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Abstract 
Introduction:  Peripheral Artery Disease (PAD) is a manifestation of progressive 
atherosclerosis involving the main conduit arteries supplying the lower extremities.  It is 
well known that atherosclerotic cardiovascular disease including PAD, is related partly to 
vascular inflammation and oxidative stress.  Treadmill walking exercise to moderate 
claudication pain is considered the gold standard for improving walking distance in 
patients with PAD and claudication.  Our group had previously reported that non-
ischemia inducing upper body ergometry exercise training improves pain-free and 
maximal walking distance similar to ischemic inducing treadmill exercise training in 
patients with claudication.  The influence of ischemic and non-ischemic inducing 
exercise training on systemic inflammation and vascular oxidative stress remains to be 
fully elucidated.  Methods:  A total of 75 patients (59 male and 16 female) with 
symptomatic PAD from the randomized controlled trial, Exercise Training to Reduce 
Claudication (EXERT), were used in a secondary analysis of inflammation and oxidative 
stress.  Analysis of plasma for TNFα, IL-10, and F2Isoprostane were performed at 
baseline and following 12 weeks of moderate intensity, claudication inducing treadmill 
training (T), upper body ergometry training (UBE), or usual care (C).  Analysis of 
covariance was used to evaluate changes among groups for all biomarkers following 
intervention, using baseline level as a covariate.  Pearson’s correlation coefficient was 
used to assess correlation among baseline plasma biomarkers and physical and 
physiological variables. Results:  After 12 weeks of intervention, all patients, regardless 
of the group increased TNFα levels.  In particular, patients randomized to the UBE group 
significantly increased TNFα levels compared to the control groups after adjusting for 
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baseline TNFα and allopurinol (a significant covariate).  Participants in the treadmill 
group had non-significant increases in IL-10, while all groups showed non-significant 
decreases in F2 Isoprostanes.  Additionally there was no significant correlation between 
baseline plasma inflammatory and oxidative stress biomarkers, with physical and 
physiological variables such as ankle-brachial index, pain-free walking distance, and 
maximal walking distance at baseline.  However, body mass index was significantly 
correlated to baseline TNFα levels (r=0.228, p=0.05).  Conclusion:  Moderate intensity 
UBE training appears to significantly increase the proinflammatory cytokine TNFα 
compared to a control group in patients with symptomatic PAD.  However, all groups 
increased TNFα after 12 weeks of intervention, which contradicts the deemed anti-
inflammatory effect of aerobic exercise training.  It is clear that further study is required 
to establish if exercise training in patients with claudication is anti-inflammatory. 
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Definitions & Abbreviations 
 
Acute Phase Reactant – Proteins that are secreted into the blood in increased or decreased 
quantities by hepatocytes in response to trauma, inflammation, or disease. These proteins 
can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase 
proteins have been used to diagnose and follow the course of diseases or as tumor 
markers. 
Asymmetric dimethylarginine (ADMA) – A protein found in plasma that is a known 
competitive inhibitor of eNOS, thereby reducing the bioavailability of nitric oxide and 
the promotion of endothelial dysfunction. 
C-Reactive Protein - A acute phase reactant plasma protein that circulates in increased 
amounts during inflammation and after tissue damage. 
Catalase - An oxidoreductase that catalyzes the conversion of hydrogen peroxide to water 
and oxygen.  
Cellular Adhesion Molecule – Surface ligands, usually glycoproteins, that mediate cell-
to-cell adhesion. Their functions include the assembly and interconnection of various 
vertebrate systems, as well as maintenance of tissue integration, wound healing, 
morphogenic movements, cellular migrations, and metastasis. 
Chronic (Systemic) inflammation - A pathological process characterized by injury or 
destruction of tissues caused by a variety of cytologic and chemical reactions mediated 
by cytokines and immunoregulators.  
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Claudication - Claudication (symptomatic PAD) comes from the Latin word "to limp” 
and can be classified as classic or atypical.  Classic claudication is often described as 
crampy leg pain (typically in the calf) that occurs during exercise, especially walking due 
to a mismatch between oxygenated blood supply and skeletal muscle mitochondrial 
demand. About a third to a half of patients with PAD have this symptom.  Atypical 
symptoms (often described in non-calf muscle groups) may be felt as pain, achiness, a 
sense of fatigue, or nonspecific discomfort that occurs with exercise. Symptoms go away 
only with rest, within several minutes. Symptoms may only initially be present when 
walking uphill, walking faster, or walking for longer distances. 
Copper/Zinc Superoxide Dismutase (Cu/ZnSOD) - An oxidoreductase that catalyzes the 
reaction between superoxide anions and hydrogen to yield molecular oxygen and 
hydrogen peroxide. The isoform of this enzyme, which is found in the cytosol, protects 
the cell against dangerous levels of superoxide. 
Cyclooxygenase (COX) - Enzyme complexes that catalyze the formation of 
prostaglandins (such as prostacyclins, thromboxanes, and prostanoids) from the 
appropriate unsaturated fatty acid, molecular oxygen, and a reduced acceptor.  COX is a 
well-known enzymatic source of superoxide. 
Cytokine - Non-antibody proteins secreted by inflammatory leukocytes and some non-
leukocytic cells that act as intercellular mediators. They differ from classical hormones in 
that they are produced by a number of tissue or cell types rather than by specialized 
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glands. They generally act locally in a paracrine or autocrine rather than endocrine 
manner. 
E-Selectin - Cell adhesion molecule and CD antigen that mediates neutrophil, monocyte, 
and memory T-cell adhesion to cytokine-activated endothelial cells. 
Endothelial Dysfunction – a disorder of the inner lining of the artery that is detected as 
the presence of reduced vasodilating response to endothelial stimuli, and has been 
observed to be associated with major cardiovascular risk factors, such as aging, 
hyperhomocysteinemia, postmenopause state, smoking, diabetes, hypercholesterolemia, 
inflammation, oxidative stress and hypertension. 
Endothelial Nitric Oxide Synthase (eNOS) - A calcium-dependent enzyme that catalyzes 
the conversion of L-arginine and oxygen to produce citrulline and nitric oxide.  This 
particular isoform of NOS is located in the endothelium and is also referred to in the 
literature as the type III form. 
Fibrinogen – Plasma glycoprotein clotted by thrombin, composed of a dimer of three 
non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide 
bonds. Fibrinogen clotting is a sol-gel change involving complex molecular 
arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, 
the proteolytic action of other enzymes yields different fibrinogen degradation products 
Free Radical - Highly reactive molecules with an unsatisfied electron valence pair. Free 
radicals are produced in both normal and pathological processes. They are proven or 
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suspected agents of tissue damage in a wide variety of circumstances including radiation, 
damage from environment chemicals, and aging 
Glutathione - A tripeptide with many roles in cells. It conjugates to drugs to make them 
more soluble for excretion, is a cofactor for some enzymes, is involved in protein 
disulfide bond rearrangement and reduces peroxides 
Glutathione Peroxidase (GPx) - An enzyme catalyzing the oxidation of 2 moles of 
glutathione in the presence of hydrogen peroxide to yield oxidized glutathione and water 
Hydrogen Peroxide (H2O2) – Compound that is classified as a reactive species (due to its 
strong ability to oxidize cellular components), but is not considered a free radical.  
Hydrogen peroxide is essential in redox signaling, particularly in pathways the elicit 
mitochondria biogenesis, and is therefore essential for human life. 
Hydroxyl Radical (OH)– Free radical that is a potent oxidizing agent, particularly of 
phospholipids.  Hydroxyl radical is strongly linked to the lipid peroxidation cascade of 
cell membranes. 
Inducible Nitric Oxide Synthase (iNOS) - A calcium-independent subtype of nitric oxide 
synthase that may play a role in immune function. It is an inducible enzyme whose 
expression is transcriptionally regulated by a variety of proinflammatory cytokines such 
as TNF alpha, results in the formation of superoxide. 
Interleukin (IL) – Soluble factors which stimulate growth-related activities of leukocytes 
as well as other cell types. They enhance cell proliferation and differentiation, DNA 
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synthesis, secretion of other biologically active molecules and responses to immune and 
inflammatory stimuli. 
Interleukin 1 Beta (IL-1B) – A soluble factor produced by monocytes; macrophages, and 
other cells which activates T-lymphocytes and potentiates their response to mitogens or 
antigens.  The IL-1 beta subtype is known as a proinflammatory cytokine and 
intermediate of the inflammatory cascade. 
Interleukin 6 (IL-6) –  A cytokine that stimulates the growth and differentiation of B-
lymphocytes and is also considered a proinflammatory cytokine. IL-6 is produced by 
many different cells including T-lymphocytes; monocytes; and fibroblasts, however, as a 
myokine, IL-6 is believed to exhibit anti-inflammatory properties. 
Interleukin 10 (IL-10) – A cytokine produced by a variety of cell types, including T-
lymphocytes; monocytes; dendritic cells; and epithelial cells that exerts a variety of anti-
inflammatory and immunoregulatory. 
Ischemic Preconditioning (IPC) – A technique in which tissue is rendered resistant to the 
deleterious effects of prolonged ischemia and reperfusion by prior exposure to brief, 
repeated periods of vascular occlusion 
Ischemia/Reperfusion Injury (I/RI) - Adverse functional, metabolic, or structural changes 
in ischemic tissues resulting from the restoration of blood flow to the tissue (reperfusion), 
including swelling; hemorrhage; necrosis; and damage from free radicals. The most 
common instance is myocardial I/RI. 
xv!
Lipoxygenase (LOO) - An enzyme of the oxidoreductase class that catalyzes reactions 
between linoleate and other fatty acids and oxygen to form hydroperoxy-fatty acid 
derivatives.  LOO is a common enzymatic source of ROS. 
Manganese Superoxide Dismutase (MnSOD) – An oxidoreductase that catalyzes the 
reaction between superoxide anions and hydrogen to yield molecular oxygen and 
hydrogen peroxide. The isoform of this enzyme, which is found in the mitochondria, 
protects the cell against dangerous levels of superoxide 
Maximal Walking Distance (MWD) – Distance walked (in meters) that elicits a level of 
claudication resulting in the termination of walking.  
Mitochondrial Dysfunction (Myopathy) - Any of a group of myopathies associated with 
an increased number of abnormal mitochondria in muscle fibers with diminished enzyme 
activity and manifested by exercise intolerance, weakness, lactic acidosis, and cardiac 
abnormalities.  Muscle biopsy tests for cellular respiration or DNA deletions may be used 
as invasive tests to diagnosis presences of disease. 
NADPH oxidase (NOX) – A flavoprotein enzyme that catalyzes the univalent reduction 
of oxygen using NADPH as an electron donor to create superoxide anion. The enzyme is 
dependent on a variety of cytochromes. 
Oxidative Stress - A disturbance in the prooxidant-antioxidant balance in favor of the 
former, leading to potential damage. Indicators of oxidative stress include damaged DNA 
bases, protein oxidation products, and lipid peroxidation products. 
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P-Selectin - Cell adhesion molecule and CD antigen that mediates the adhesion of 
neutrophils and monocytes to activated platelets and endothelial cells 
Pain Free Walking Distance (PFWD) – Distance walked (in meters) that elicited the first 
symptoms of claudication.  
Plasminogen Activator Inhibitor-1 (PAI-1) – A member of the serpin family of proteins. 
It inhibits both the tissue-type and urokinase-type plasminogen activators. 
Prostacyclin (PGI2) - A prostaglandin that is a powerful vasodilator and inhibits platelet 
aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in 
human vascular tissue. 
Reactive Oxygen Species (ROS) – Molecules or ions formed by the incomplete one-
electron reduction of oxygen. These reactive oxygen intermediates include singlet 
oxygen; superoxides; peroxides; hydroxyl radical; and hypochlorous acid. They 
contribute to the microbicidal activity of phagocytes, regulation of signal transduction 
and gene expression, and the oxidative damage to nucleic acids; proteins; and lipids.  
Soluble Intracellular Adhesion Molecule 1 (sICAM-1) - A cell-surface ligand involved in 
leukocyte adhesion and inflammation. Its production is induced by gamma-interferon and 
it is required for neutrophil migration into inflamed tissue 
Soluble Vascular Adhesion Molecule 1 (sVCAM-1) – Cytokine-induced cell adhesion 
molecule present on activated endothelial cells, tissue macrophages, dendritic cells, bone 
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marrow fibroblasts, myoblasts, and myotubes. It is important for the recruitment of 
leukocytes to sites of inflammation. 
Superoxide (O2-) -  Highly reactive compounds produced when oxygen is reduced by a 
single electron. In biological systems, they may be generated during the normal catalytic 
function of a number of enzymes and during the oxidation of hemoglobin to 
methemoglobin.  
Thromboxane A2 (TXA2) - An unstable intermediate between the prostaglandin 
endoperoxides and thromboxane B2.  TXA2 is a potent inducer of platelet aggregation and 
causes vasoconstriction. 
Tissue Plasminogen Activator (tPA) – A proteolytic enzyme in the serine protease family 
found in many tissues, which converts plasminogen to fibrinolysin. It has fibrin-binding 
activity and is immunologically different from urokinase-type plasminogen activator. 
Tumor Necrosis Factor Alpha (TNFα) - Serum glycoprotein and proinflammatory 
cytokine produced by activated macrophages and other mammalian mononuclear 
leukocytes. It has necrotizing activity against tumor cell lines and is highly involved in 
the pathogenesis of atherosclerosis. 
vonWillebrand Factor (vWF) - A high-molecular-weight plasma protein, produced by 
endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor 
complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin 
activity as well as the immunologically distinct antigenic determinants. It functions in 
adhesion of platelets to collagen and hemostatic plug formation. 
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Xanthine Oxidase (XO) - An iron-molybdenum flavoprotein containing flavin-adenine 
dinucleotide that oxidizes hypoxanthine, some other purines and pterins, and aldehydes.  
XO is a potent source of superoxide that is produced during I/RI
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Chapter 1 
Background/Introduction 
Peripheral Artery Disease (PAD) is a manifestation of progressive atherosclerosis 
involving the main conduit arteries supplying the lower extremities.  Major risk factors 
include aging, smoking, type 2 diabetes mellitus, hypertension, and dyslipidemias,1 which 
are associated with increased rates of cardiovascular ischemic events and death.2 PAD 
affects approximately 8 million people in the United States, including 12-20% of 
individuals older than age 65.3,4 Symptomatic PAD, (also referred to as claudication) is 
associated with reduced functional capacity,5-7 walking ability,8-10 and quality of life.11-16 
Claudication, which is Latin for limping, and can be classified as classic or atypical, 
results from a mismatch between oxygenated blood supply and demand, that culminates 
in leg pain during walking-type activity.  Following a short duration of rest (typically 3-5 
minutes), the ischemia-induced leg pain ceases and walking is typically resumed.   
Research over the past two decades has established that the pathophysiology and 
progression of atherosclerotic cardiovascular diseases including PAD, is related partly to 
vascular inflammation and oxidative stress,17-21 and is shown in Figure 1.   
Walking exercise has been considered for the past decade as a primary treatment 
for symptomatic PAD to improve walking distance, and is considered a class I, level A 
evidence recommendation by the American Heart Association for improving walking 
capacity in patients with claudication.22 The three-fold goals of exercise as a treatment for 
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claudication as reviewed by Hamburg and colleagues, include: 1) to decrease the 
occurrence of cardiovascular events, 2) reduce limb symptoms: and 3) prevent or lessen 
physical disability, and enhance walking ability and functional capacity.23   Exercise also 
is generally considered to have anti-inflammatory24-32 and antioxidant33,34 properties, which 
are postulated to be part of its wide array of cardioprotective effects.35 Indeed, 
randomized, controlled, clinical trials have demonstrated that moderate intensity, aerobic 
exercise training significantly reduce levels of proinflammatory cytokines in both healthy 
individuals36 and in patients with overt cardiovascular diseases (CVD) albeit with some 
variability in findings in other populations.37-39 Treadmill walking has been the most 
studied and utilized form of exercise as a treatment for PAD.  In 2008, a Cochrane review 
assessed randomized controlled trials (n=22) that focused on various exercise regimens 
(walking, ergometry, polestriding, and resistance training), medical, and surgical therapy 
with the primary goal to compare their relative effectiveness in improving walking 
ability.  The findings within this review provided additional support for the use of 
exercise therapy as a primary treatment for symptomatic PAD, and suggest that patients 
with claudication may see improvements in maximal walking distance (MWD) of 50-
200% after participation of long-term treadmill training.40   Although the Cochrane 
review40 did not make conclusions in regards to exercise training vs. surgical 
interventions due to lack of head to head trials, studies published after this publication 
suggest that exercise training in the form of supervised walking results in superior 
improvements in maximal walking distance (MWD) compared to surgical 
intervention.41,42  
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Although the primary mechanism underlying exercise-induced improvements in 
walking distance and functional capacity in patients with PAD is not fully understood, the 
evidence is robust, and is the topic of several reviews.23,43-45 The traditional treadmill 
rehabilitation protocol involves the PAD patient to walk to a moderate level of 
claudication at which point the walking bout is terminated, and the patient is to sit down 
and rest until the leg symptoms are alleviated, at which point walking exercise is once 
again performed.22 This pattern of work/rest intervals continues throughout the typical 
sixty-minute exercise training session.22 However, the effects of the repeated ischemia-
reperfusion cycle brought on by treadmill exercise may have on systemic inflammation 
and oxidative stress in this population are not well understood.  Currently two theories 
exists: 1) skeletal muscle ischemia-inducing treadmill walking, to a level of moderate 
claudication, is postulated to elicit a response known as ischemic preconditioning (IPC) 
with the subsequent reduction of proinflammatory cytokines and oxidative damage,46,47 
and 2) ischemia-inducing treadmill exercise may promote ischemia/reperfusion injury 
(I/RI), which can be destructive to the vascular endothelium and skeletal muscle,48 and is 
demonstrated in our theoretical framework (Figure 2). Although the concept of exercise 
induced IPC is well-documented in cardiac muscle,49,50  it has been far less studied and 
understood in skeletal muscle, particularly with the induction of claudication.51,52 In 
regards to I/RI, although highly plausible, patients with claudication are exposed to this 
phenomenon on a daily basis yet clinical trials show significantly improved walking 
performance after treadmill training,6,40,42,53-57 which suggests that inflammation and 
oxidative stress may not be a mediator of these outcome in PAD patients. Regardless in 
the past decade, an alternative, non-ischemic mode of exercise training, in the form of 
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upper body ergometry (UBE) also has been shown to improve walking ability in patients 
with claudication.52,58-60 Although the exact mechanisms that promote the increased 
walking capacity in patients with claudication, following chronic UBE training are not 
fully understood, adaptations are postulated to be at least partially related to systemic 
anti-inflammatory and antioxidant effects.52,61 
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Statement of Purpose 
The primary objective of this secondary analysis of data from the controlled, 
randomized study entitled Exercise Training to Reduce Claudication (EXERT) 
(NCT00895635) is to compare the relative efficacy of 12 weeks of UBE training vs. 
treadmill walking as compared to a control group (receiving standard medical care) on 
plasma biomarkers of systemic inflammation and oxidative stress in patients with 
symptomatic PAD through the following specific aims.  Another objective was to 
determine if an association between baseline levels of inflammation and walking 
performance exist in patients with PAD. 
Primary Aim. 
The primary aim was to compare the effect of 12 weeks of supervised, non-
ischemic upper body ergometry training (n=30) to ischemic-inducing treadmill exercise 
training (n=30) versus a control group (n=15) receiving “usual care”, on inflammation as 
measured by plasma levels of TNFα and IL-10 and oxidative stress via circulating levels 
of F2Isoprostanes (a marker of lipid peroxidation).  
Secondary Aim. 
The secondary (exploratory) aim was to evaluate the association among systemic 
inflammation, maximal walking distance (MWD) and pain free walking distance 
(PFWD) in patients with claudication (n=75) prior to initiation of a moderate intensity 
aerobic exercise training program.   
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Hypotheses 
Primary Hypotheses. 
It was hypothesized that: 
1. After 12 weeks of supervised exercise training, participants randomized to UBE 
training would show a greater reduction in plasma biomarkers of inflammation 
(TNFα) and oxidative stress (F2Isoprostanes) compared to individuals in the 
treadmill training and control groups. 
2. After 12 weeks of supervised, exercise training participants randomized to UBE 
training would show a greater improvement in the plasma levels of anti-
inflammatory cytokines (IL-10) as compared to individuals in the treadmill 
training and control groups. 
Secondary Hypothesis. 
It was postulated that patients with greater baseline plasma biomarkers of inflammation 
(TNFα) will exhibit shorter MWD and pain free walking distance (PFWD) compared to 
individuals with less baseline inflammation.   
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Chapter II 
Background & Literature Review 
This chapter is divided into the following sections: 
1. Pathophysiology of Atherosclerosis: From Atherogenesis to Thrombosis with 
Emphasis on Inflammation and Oxidative Stress Contributors 
2. Inflammation & Oxidative Stress in PAD: Pathophysiology, Sources, and 
Consequences 
a. Cytokine Biomarkers of Inflammation in PAD 
b. Sources of Reactive Oxygen and Nitrogen Species (RONS) 
i. Nicotinamine Adenine Dinucleotide Phosphate (NADPH) oxidase 
ii. Xanthine Oxidoreductase (XO) 
iii. Mitochondria 
iv. Uncoupling of endothelial nitric oxide synthase (eNOS) 
v. Cyclooxygenase (COX) 
vi. Myeloperoxidase (MPO) 
vii. Lipoxygenase (LOO) & angiotensin II (AII) 
viii. Homocysteine 
c. Description of RONS Cascade 
d. Endogenous Defenses against Inflammation & Oxidative Stress 
i. Endogenous Antioxidant Defenses against Inflammation and 
RONS in the presence of Claudication 
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e. Consequences of Chronic Inflammation and Oxidative Stress Pertaining to 
the Etiology of PAD 
i. Mitochondrial Dysfunction due to Chronic Inflammation and 
Oxidative Stress 
1. Mitochondrial Dysfunction in PAD 
2. Analyses of Oxygen Kinetics in PAD 
3. Analyses of Oxidative Phosphorylation in PAD 
4. Analyses of Skeletal Muscle Enzyme Activity in PAD 
5. Conclusions from Mitochondrial Dysfunction Studies in 
PAD  
ii. Pathophysiology of Endothelial Dysfunction related to 
Inflammation and Oxidative Stress in PAD 
3. Therapeutic Effects of Exercise on Inflammation, Oxidative Stress, Antioxidant 
Capacity, and Mitochondrial and Endothelial Dysfunction, pertaining to PAD  
a. Aerobic Exercise & Indices of Inflammation 
b. Aerobic Exercise as an Antioxidant  
c. Aerobic Exercise and Skeletal Muscle Metabolic Parameters in PAD 
d. Aerobic Exercise and Endothelial Dysfunction (PAD studies) 
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Review of Literature 
Pathophysiology of Atherosclerosis: From Atherogenesis to Thrombosis with 
Emphasis on Inflammation and Oxidative Stress Contributors. 
Endothelial dysfunction has been proposed to be the first step in the initiation of 
atherosclerosis, which is often preceded by several cardiovascular risk factors including 
smoking, oxidized low density lipoprotein (LDL), hyperglycemia, hypertension, 
dyslipidemias, inflammation and elevated free radicals or oxidative stress.19 Endothelial 
dysfunction results in a cascade of events highlighted by increased membrane 
permeability, leukocyte, neutrophil, and platelet adhesion, and loss of anticoagulant and 
vasodilating capacity.  A majority of these processes are regulated by endothelial-derived 
cytokines, which are also elevated as a response to this proinflammatory state.    
Damage to the endothelium and the increased membrane permeability results in 
the infiltration of LDL into the artery intima and its subsequent oxidation.  This oxidized 
LDL is postulated to be a primary stimulus for monocyte-endothelial interactions.  Once 
adhered to the endothelium, monocytes enter the intima (diapedesis) and differentiate into 
macrophages.  Pattern recognition receptors including scavenger receptor A, cluster of 
differentiation 36 (CD-36, and toll-like receptors (TLR) on the macrophage recognize 
oxidized LDL leading to their uncontrolled phagocytosis. If the LDL particles cannot be 
mobilized from the cell in a sufficient extent, it accumulates and ultimately the lipid-
engorged macrophages form the foam cells in the artery intimas.18  In addition to innate 
immune cells, cells of the adaptive immune system such as CD 4+ (helper) T cells and to 
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a lesser extent B cells are also found in the initial sites of the atherosclerotic lesion.62 T-
cells are reactive to oxidized LDL and heat shock protein 60 (HSP-60), which serve as 
antigens which are bound to major-histocompatibility-complex class II molecules.62 This 
ligation results in a cascade that elicits a type 1 T helper response (Th1) characterized by 
the production of interferon γ, a cytokine that has the following inflammatory and 
atherosclerotic effects:  macrophage activation, augmentation of the synthesis of TNFα, 
IL-1ß, and increased efficiency of antigen presentation.62 
Activated macrophages, Th1, and foam cells are all potent generators of 
proinflammatory cytokines such as TNFα, IL-1ß, and interleukin 6 (IL-6),19,63 which result 
in a positive feedback loop that promote the following vascular maladaptations: increased 
LDL uptake and oxidation (via increased expression of acetyl-coA acetyltransferase-1), 
increased expression of cellular adhesion molecules, and the attraction, adhesion, 
activation, and infiltration of neutrophils.17,64   Reduced Nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase (from activated neutrophils), inducible nitric 
oxide synthase (iNOS), and xanthine oxidoreductase (XO), all of which are well-known 
producers of the potent radical superoxide (O2-), and are all upregulated by the 
proinflammatory cytokine TNFα.65,66 These processes demonstrate the intricate 
relationship of inflammation and oxidative stress to the generation and accumulation of 
foam cells in the artery intimas. 
Initial accumulation of foam cells results in the proliferation of smooth muscle 
cells, migration from the arteries’ media, and culminates with the walling off of the fatty 
streaks with connective tissue, known as the fibrous cap.  This atheroma then is 
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considered an advanced, complicated lesion, and at some point when the artery can no 
longer compensate by dilation, the lesion may intrude into the lumen to reduce blood 
flow.19 Arterial occlusions of about 70% in coronaries may result in angina pectoris, in 
iliac and femoral arteries in claudication, or in cerebral arteries in a transient ischemic 
attack, hallmarks of coronary heart disease, PAD, and stroke respectively.  The advanced 
lesion is also subject to remodeling, a process primarily regulated by inflammatory 
cytokines.  In this proinflammatory environment, cytokines such as TNFα both impairs 
the smooth muscle cell production of collagen (required for fibrous cap repair) and 
directly promotes the disruption of a thin, vulnerable fibrous cap in a lipid laden lesion.18 
C-Reactive Protein (CRP), an acute phase protein whose release is promoted by TNFα 
and IL-1ß,67 can exacerbate the plaque disruption via the upregulation of matrix 
metalloproteinase-1, an enzyme known to degrade the basement layer of the endothelium 
and the fibrous cap of the atheroma.68    Disruption of a vulnerable plaque culminates in 
thromboembolism, which potentially can cause an acute coronary event, progression to 
ischemic rest pain in the limbs, major stroke, and if untreated, sudden death. TNFα and 
CRP both play an active role in the thrombogenic process following plaque rupture 
through the upregulation of tissue factor (TF)69 and plasminogen activator inhibitor-1 
(PAI-1).70 TF is a protein that initiates the extrinsic clotting cascade through the formation 
of the TF-factor VII complex, while PAI-1 inhibits the action of tissue plasminogen 
activator (tPA), which ultimately prevents the removal of fibrin by the protein plasmin.71   
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Inflammation & Oxidative Stress in PAD: Pathophysiology, Sources and 
Consequences 
Contributors to Inflammation & Cytokine Biomarkers in Patients with PAD 
As mentioned in the introduction PAD is an atherosclerotic occlusive disease 
involving major arteries supplying the lower extremities.  PAD is associated with high 
levels of inflammation, as indicated by elevated proinflammatory biomarkers, including 
TNFα, IL-1, CRP, IL-6, soluble vascular cellular adhesion molecule-1 (sVCAM-1), 
soluble intercellular adhesion molecule-1 (sICAM-1), and fibrinogen.72-78   Recent data 
from the National Health and Nutrition Examination Survey (NHANES) published in 
2005 (n=4787) suggests that inflammation is independently associated with PAD. This 
was indicated by a multivariate adjusted odds ratios of PAD associated with the highest 
versus the lowest quartile of CRP, fibrinogen, and leukocyte count were 2.14 (95% CI 
1.41 to 3.25), 2.49 (95% CI 1.27 to 4.85), and 1.67 (95% CI 0.84 to 3.31) respectively 
(each p trend ˂ 0.05 across quartiles).77    This multivariate model was adjusted for age, 
gender, race/ethnicity, education, smoking status, diabetes, physical inactivity, total 
cholesterol, body mass index, and systolic blood pressure.77  
Inflammation, in addition to its role in the etiology of PAD, is postulated to play a 
major role in the atherosclerotic-related progression, severity79 and clinical outcomes such 
as death.19,80  In particular, CRP and fibrinogen are highly correlated with markers of 
endothelial dysfunction, a hallmark of PAD, independent of the traditional risk factors 
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discussed above.72   Further, levels of CRP, sICAM-1, sVCAM-1 are negatively 
correlated to the severity of circulatory impairment or atherosclerotic burden as assessed 
by the ankle-brachial index (ABI), in patients with claudication, but not asymptomatic 
PAD.79  High levels of inflammation, particularly associated with elevated levels of 
TNFα, are also known to weaken the thin fibrous cap that surrounds the lipid rich 
atheromata.81   Erosion or disruption of a vulnerable plaque in the periphery may result in 
a thromboembolism, and thereby acutely increases the risk for an acute coronary event, 
pulmonary embolism, or progression of PAD to critical limb ischemia, all conditions 
known to significantly elevate the risk of death. 
Inflammation can both initiate atherosclerotic PAD and exacerbate atherosclerotic 
burden through several mechanisms which may include; production of cytokines, 
recruitment of macrophages within the vascular wall, smooth muscle and leukocyte 
proliferation and chemoattraction, and increased endothelial membrane permeability.77   
These mechanisms may be a direct result of the atheroma or potentially due to I/RI that 
occurs with both ambulatory activities of daily living and acute bouts of exercise.  In the 
former condition it is believed that the macrophages that have infiltrated the 
atherosclerotic plaque (stimulated by the presence of oxidized low density lipoprotein) 
cause the secretion of proinflammatory cytokines including TNFα, IL-1ß or IL-6 from the 
lesion.82  IL-6, whose production may be mediated by TNFα, which also a known 
stimulator for the release of CRP and fibrinogen from the liver.  All three inflammatory 
biomarkers likely reflect the environment of atherosclerotic burden in patients with 
claudication as mentioned above in the NHANES cohort77 above. 
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A second source of inflammation is I/RI, a phenomenon that exists in the daily 
life of those with claudication.83,84   During walking bouts the energy requirements of the 
lower extremity myocytes in patients with claudication exceeds the capabilities of the 
vascular system to deliver oxygen, due primarily to atherosclerotic plaque occlusion but 
also to impaired vasodilatory capabilities of the arterial system due to endothelial 
dysfuction.  The mismatch between skeletal muscle oxygen demand and oxygen delivery 
causes ischemia and claudication, which is exacerbated until the point where ambulation 
must cease.  Upon rest, the metabolic demands of the lower extremity skeletal muscles 
return to baseline, and a slow return blood (and therefore oxygen) returns to the 
previously ischemic muscle (i.e. reperfusion), in an attempt to regain cellular 
homeostasis.  This return of blood and oxygen, known as the ischemic window, which is 
dependent upon disease severity and amount of exercise accumulated, may take 
anywhere from five to ten minutes.85  However, the return of oxygen to the previously 
ischemic muscle has the potential to intensify damage to myocytes.  Park and colleagues86 
refer to this as reperfusion injury or the metabolic, functional, and structural 
consequences of restoring arterial flow, which theoretically can be avoided by modifying 
the conditions of reperfusion. 
Major characteristics of I/RI are an acute inflammatory phase, most notably 
attributed to the release of proinflammatory cytokines (including, but not limited to TNFα 
and IL-6) and the development of reactive oxygen and nitrogen species (RONS) 
developed through enzymatic and non-enzymatic mechanisms.87  Primary implemented 
enzymatic sources include: NADPH oxidase (NOX), xanthine oxidase (XO), 
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cyclooxygenase (COO), and lipoxygenase (LOO), while the leaky mitochondria are the 
primary non-enzymatic sources of RONS.  The initiation of inflammation with I/RI is an 
event that culminates with neutrophil respiratory burst and oxidative cell damage that 
once again illustrates the intricate relationship between inflammation and RONS.88  The 
mechanisms behind the oxidative damage promoted by the activated neutrophil 
(neutrophil attraction, adhesion, rolling, and respiratory burst) are complex and beyond 
the scope of this thesis. For a more detailed depiction of these processes the reader is 
encouraged to read works by Blankenberg and colleagues.17   The resulting I/RI, 
regardless of the source causes damage to both the skeletal and cardiac muscle86,89 and 
microvasculature.87   
The main manifestation of I/RI to the vasculature is an impaired endothelial 
dependent NO-mediated relaxation of smooth muscle to all receptor-dependent 
vasodilators, likely due to the overproduction of superoxide anions (O2-) by post-ischemic 
endothelial cells.90 Another hallmark of I/RI, increased leukocyte-endothelial adhesion 
and activation, results in capillary malperfusion (and tissue hypoxia) primarily due to the 
plugging of capillaries by the stiffer, activated leukocytes.91 Capillary malperfusion (due 
to I/RI) also may arise from the accumulation of interstitial fluid (oedema) caused by a 
leukocyte-dependent enhancement of protein and fluid leakage in post-ischemic venules 
that promotes the compression of the microvasculature, thereby impeding the movement 
of oxygenated red blood cells and other blood elements within the capillaries.91 This 
thereby limits the amount of oxygen available to diffuse into the myocyte.  Lastly, some 
research supports skeletal muscle injury secondary to increased production of ROS by 
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proinflammatory cytokines and dysfunctional mitochrondria; both associated with 
ischemia and I/RI.92 Skeletal muscle injury may range from peripheral neuropathy93,94 to 
damage resulting in impaired aerobic metabolic capabilities.95-98 The forms of endothelial 
and mitochrondial dysfunction (discussed in detail later in this review) are major 
contributors to claudication. 
Sources of RONS 
NADPH Oxidase (NOX) 
NOX is a very prevalent source of O2− that is activated primarily via 
inflammatory (cytokines) and vasoactive (e.g. angiotensin II or AII) factors.99  During 
I/RI and other types of muscle injury, myocytes and other cells produce and release a 
number of proinflammatory cytokines, such as IL-1, IL-6, IL-8, and TNFα, which 
promote the chemoattraction of the neutrophil to the endothelium.100   These 
proinflammatory cytokines are the stimulus for the upregulation of adhesion factors 
(selectins) on the endothelial surface required for neutrophil adhesion.101   E-Selectin is 
found on the activated endothelium while P & L-Selectin reside on the surface of the 
neutrophil.24,64,102   Upon “capturing” or “loose” binding to the endothelium, the selectins, 
primarily P-selectin, mediate neutrophil rolling necessary for activation of NOX.103,104   
Firm adhesion then is mediated by E-selectin and cellular adhesion molecules  (ICAM-1 
and VCAM) on the endothelium, integrins and CD11/CD18 complex on the 
neutrophils,105,106 the latter being upregulated by P-Selectin and platelet activating factor 
(PAF).  Once fully adhered to the endothelium, the now activated neutrophil can 
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transmigrate through the activated endothelium and into the source of activation.105   At 
the site of inflammation, the activated neutrophils undergo a respiratory burst, an 
autoimmune response characterized by the rapid release of ROS (primarily O2−  and other 
oxidants such as myeloperoxidase) (MPO), designed to rid the area of cellular damage 
and debris.  Furthermore the O2− generation from respiratory bursts may promote further 
neutrophil attraction, resulting in a positive feedback loop, characterized oxidative stress-
induced cellular damage.107  
Although the exact mechanisms of the leukocyte cascade are not universally 
accepted, it is generally agreed upon that inflammation is a necessary stimulus for the 
adhesion and activation of the neutrophils and subsequent oxidative burst.  Several 
studies have found significantly elevated plasma or serum levels of selectins,78,108 
cytokines,109,110 adhesion molecules75,78,110,111 in PAD patients with claudication compared to 
healthy age-matched controls.   Further, resting levels of activated neutrophils are 
elevated in patients with PAD.112 This suggests that even at rest, patients with PAD likely 
are exposed to an internal environment that promotes neutrophil activation, which is not 
surprising since atherosclerosis is generally recognized as an inflammatory disease. 
Xanthine Oxidase (XO) 
Xanthine dehydrogenase (XD) and xanthine oxidase (XO) are two isoforms of 
xanthine oxidoreductase, with the former implemented in oxidative stress,113 particularly 
with coronary artery disease.114,115 Both isoforms are known most notably for their roles in 
purine metabolism, with uric acid as the end product.  During exercise, particularly 
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exercise inducing ischemia, oxygen deprivation leads to the initiation of anaerobic 
glycolysis, resulting in lactate production and acidosis.  As a result of the inefficiency of 
glycolysis to maintain ATP production, ATP levels fall causing the adenine nucleotides 
to be catabolized into adenosine, inosine, and hypoxanthine.116,117 A buildup of these 
aforementioned metabolites is due primarily to the ischemic environment114-116 that 
prevents the necessary oxidative phosphorylation to replenish myocyte ATP levels.  In 
addition, the ischemic environment leads to the protease-induced transformation of 
xanthine oxidoreductase from the dehydrogenase to oxidase form.  Upon reperfusion, the 
necessary substrate for XO, oxygen, returns and leads to the generation of O2−.118  
Respiring Mitochondria 
During normal cellular respiration, oxygen is utilized by the mitochondria and at 
the terminal step of oxidative phosphorylation it is reduced to water.  During this process, 
electrons from reduced nicotinamide adenine dinucleotide (NADH) or flavin adenine 
dinucleotide (FADH2) via the Krebs Citric Acid Cycle (isocitrate dehydrogenase, alpha 
ketoglutarate dehydrogenase, succinic dehydrogenase, and malate dehydrogenase) and 
glycolytic (glyceraldehyde 3 phosphate dehydrogenase) reactions with the help of the 
malate-aspartate shuttle, are transported to the ETC (NADH to complex I and FADH2 to 
complex II).  Electrons travel along the respiratory chain transferring electrons from 
complex to complex (NADH ubiquinone oxidoreductase, succinate ubiquinone 
oxidoreductase, ubiquinone-cytochrome c oxidase, and cytochrome c oxidase) 
establishing proton gradients at complexes I, III, and IV which power complex V (ATP 
synthase) which results in oxidative phosphorylation.119  
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However, this is an imperfect process since the electron chain is “leaky,” resulting 
in a loss of electrons into the matrix, and potentially in the cytosol of the cell, resulting in 
not only a decrease in energy production, but also the reduction of oxygen into ROS 
including O2−.  It is estimated that at rest 90% of ROS occurs due to the escape of 
electrons from the ETC and that 1-4% of oxygen is reduced to superoxide during 
oxidative phosphorylation.120   Additionally, during ischemia, the moderate ROS 
generation of O2− is most likely from a mitochondria source.99,121 The general consensus is 
that complexes I and III are primarily the sites of electron leakage and generation of the 
ROS involved in healthy aging,122,123 but complex IV also may be involved as well in the 
etiology of certain diseases including PAD.97   An increase in metabolic rate with exercise 
results in macronutrient breakdown and flux of substrate (NADH, FADH2) into the 
mitochondria respiratory chain.  Although plausible, state 4 respiration may not result in 
greater electron leakage compared to state 3, and O2− production, but this is not 
conclusive.124   Furthermore, O2− production from the respiring mitochondria will first 
damage the complexes of the ETC, which are in close proximity, and can lead to a 
viscous cycle with the potential of the development of mitochondrial dysfunction. 
Uncoupled eNOS 
Uncoupled eNOS refers to the oxidation of eNOS cofactor tetrahydrobiopterin 
(BH4) by O2− or peroxynitrite (ONOO-), which results in the production of O2− from 
eNOS to a greater extent than that of nitric oxide (NO).125-127   The pathophysiology of the 
uncoupling of eNOS and O2− is a common cause of endothelial dysfunction, and is 
discussed later in this review. 
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Myeloperoxidase (from within the atheroma)-releases hypochlorous acid 
MPO is a peroxidase enzyme that is expressed within the neutrophil granulocyte 
and secretes a number of oxidants, primarily the production of hypochlorous acid and 
hydrogen peroxide (H2O2), that directly contribute to lipid peroxidation and post-
translational modifications of proteins.128   MPO is also expressed within the atheroma 
and may directly promote atherogenesis.129  MPO may directly be involved in the etiology 
of atherosclerosis through several mechanisms which include: oxidation of LDL, 
promotion of endothelial dysfunction, and development of vulnerable plaques.128,130   
 
Lipoxygenase & AII 
AII is the principal product of the renin-angiotensin-aldosterone system and is 
recognized primarily for its promotion of vasoconstriction and peripheral vascular 
resistance.  Additionally AII is also for maintenance of salt and water homeostasis and 
vascular remodeling through aldosterone secretion and angiogenic mechanisms.  AII is 
highly implicated in the development of hypertension, a condition that also has 
proinflammatory and pro-oxidant properties, which promotes the formation of free 
radicals, such as O2−, H2O2, and hydroxyl radicals (OH-).65,131,132   In vascular smooth 
muscle and endothelial cells it is wellknown that AII activates NADPH oxidase to 
generate ROS,133 however their production may be further mediated by multiple 
enzymatic sources.134  
Homocysteine 
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Homocysteine is a non-protein homologue of the amino acid cysteine and is 
biosynthesized from methionine.  Originally, observational epidemiological studies 
suggested that elevated homocysteine was a risk factor for cardiovascular disease, 
particularly myocardial infarction,135 but subsequently clinical trials with the amelioration 
of plasma homocysteine with B-Vitamins, have proven unsuccessful in the reduction of 
cardiovascular events.136-138 However, homocysteine may directly alter oxidative stress by 
generation of H2O2 and suppression of glutathione peroxidase (GPx), believed to 
contribute to a reduction in the bioavailability of NO.139 Additionally homocysteine 
elevation may also result in the elevation of asymmetric dimethylarginine (ADMA), 
which may be a consequence of oxidative induced damage to dimethylarginine 
dimethylaminohydrolase (DDAH) as discussed later in this review.    
RONS Cascade 
Oxygen is essential for eukaryotic life as it is used by the vast majority of 
organisms to extract energy from organic macromolecules.  Further, oxygen plays a key 
role in the protection of cellular life as a necessary component of the immune system, 
particularly the neutrophil as previously mentioned.  Because of oxygen’s readily 
bioavailability and ease of distribution, it is advantageous for these cellular processes, 
however oxygen also can accept single electrons to form unstable derivatives (i.e. free 
radicals). 
As previously mentioned, O2−, the “primary” ROS, is a product of uncoupled 
electron transport, and other enzymatic reactions within the cell.  O2− due to its relatively 
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long half-life, which optimizes diffusion capabilities within the cell, has a number of 
potential targets of oxidative damage and is therefore implicated in the pathophysiology 
of several diseases.140    Some of the damaging reactions include, but are not limited to: 
mitochondrial DNA (MtDNA),141,142  NO (forming ONOO-),127  and lipid peroxidation in 
cell membranes.143,144 In healthy populations, most of the O2− produced during cellular 
respiration is dismutated into the “secondary” ROS H2O2 by manganese superoxide 
dismutase (MnSOD),145 and in the mitochondrial inner membrane space by copper-
zinc/cytosolic isoform, Cu/ZnSOD 146 while O2− produced during enzymatic (NOX, XO, 
LOO) release in the cytosol is dismutated by Cu/ZnSOD.147,148  
Since H2O2 does not have any unpaired electrons it is technically not a free 
radical, but is still considered a ROS, because it is able to cross the mitochondrial 
membranes and enter the cytosol where in the presence of a transition metal (primarily 
iron) it is able to form the highly reactive OH·.   This is referred to as the Fenton reaction 
by which two molecules of H2O2  are converted to two OH· plus water.   The enzyme 
GPx catalyzes the reaction of H2O2 with the reduced glutathione (GSH) yielding water 
and oxidized glutathione (GSSH).124,149   GSSH is converted back to its reduced form 
(GSH) by glutathione reductase and the addition of substrate NADPH generated in the 
pentose phosphate pathway.150   H2O2 also can be reduced in the cytosol by catalase to 
water and oxygen.124,151   H2O2 in the presence of chloride and MPO can be converted to 
hyperchlorite, a ROS that can be particularly damaging to cellular proteins.140  
OH·, generally considered the most reactive of the ROS, reacts with whatever 
biomolecules it collides with.  Phospholipids in cell membranes and proteins are 
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generally attacked by OH·, with the former resulting in a radical chain reaction.  The 
process of radical chain reactions can be particularly damaging to cell membranes.   Lipid 
peroxidation, largely accredited to OH· 152 is initiated by OH· scavenging a hydrogen 
atom from an unsaturated fatty acid component of phospholipids. This reaction alters the 
membrane structure and rigidity resulting in the loss of key characteristics of the cell 
membrane:119 semi permeability, that results in cell dysfunction and death.  The 
exogenous antioxidant molecules vitamins E, C, as well as beta carotenes help prevent 
OH· induced cell membrane damage.153,154 Vitamin E (especially alpha tocopherol) is a 
lipid soluble vitamin, which is in close proximity to the polyunsaturated fatty acids of the 
cell membrane phospholipids, scavenge OH· thereby preventing the lipid peroxidation 
cascade.155   Ascorbic acid (vitamin C), although not lipid soluble can also protect OH· 
induced membrane damage by 2 mechanisms: react with peroxide radicals (produced in 
lipid chain reaction) formed before they reach the membrane and can also enhance 
overall antioxidant activity of vitamin E by regenerating reduced alpha tocopherol.153,154  
Reactive nitrogen species (RNS) primarily consist of NO and ONOO-.  The 
former is primarily known for its role in vascular health, particularly endothelial function 
and vasodilation.  NO, previously referred to as endothelial relaxing factor,156 is derived 
from L-arginine and tetrahydrobiopterin (BH4) in a reaction catalyzed by nitric oxide 
synthase, an enzyme with 3 isoforms.  Although the presence of NO promotes a 
vasoprotective environment, it also can act as a weak reducing agent by its reduction to 
nitric dioxide.  However, more importantly, NO can act as a scavenger of O2- to form 
ONOO-,157 another free radical that can elicit cellular damage.  NO reacts with superoxide 
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three times more rapidly than the dismutation of O2- to H2O2.140   Further, the continuous 
formation of ONOO- can be detrimental nitric oxide generation, as this process is 
implicated in the development of eNOS uncoupling, a major step in the development of 
endothelial dysfunction,127 as discussed below in greater detail. 
Endogenous Antioxidant Defenses against Inflammation and RONS are Impaired in 
Patients with Claudication 
The study of antioxidant biomarker levels in PAD at rest and immediately 
following exercise are a source of interest in PAD research, since antioxidants scavenge 
the ROS that lead to cellular damage and dysfunction.  However, as is the case with the 
direct assessment of oxidative products, due to the large number of markers and testing 
techniques, concrete conclusions may be difficult to derive.  Investigational biomarkers 
analyzed include serum levels of endogenous and exogenous antioxidants and/or their 
capacities (especially GPx, L-ascorbic acid, alkaline phosphatase, and total antioxidant 
capacity or TAC)74,83,158 and mineral cofactors (e.g. selenium).158   Biopsied skeletal muscle 
also can be analyzed to directly measure antioxidant enzyme activity and is considered a 
gold standard.  However, biopsy of muscle from the lower extremity in patients with 
claudication is very controversial due to the increased risk of poor healing, resulting in 
ulcer formation at the excision site.  Despite these risks, muscle biopsy techniques for the 
analysis of oxidative products and skeletal muscle antioxidant levels have been 
assessed.97  A relative consistent finding in the literature from such studies is that PAD 
results in a decrease in both endogenous enzymatic antioxidant and serum exogenous 
antioxidant levels.  In biopsied gastrocnemius muscle from a mix of functional and 
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critical limb ischemia subjects, Pipinos and colleagues97 found deficiencies in 
metalloenzymatic antioxidants.  Compared to healthy, age matched control subjects, 
MnSOD levels were significantly reduced in resting skeletal muscle, which likely reflects 
an impaired antioxidant system that is unable to respond to abnormal levels of ROS.97  
However, catalase and GPx levels (measured from excised gastrocnemius) were elevated 
suggesting that the impaired antioxidant defenses in PAD patients may be isolated to the 
mitochondria.  This is despite some research that suggests that PAD is associated with 
increased mitochondrial density, which implies a greater concentration of MnSOD.  In 
contrast to findings by Pipinos et al,97 research by Edwards and colleagues158 suggest that 
serum GPx levels are significantly diminished in PAD patients.  Additionally, the 
essential cofactor of GPx (selenium) is also significantly lowered in PAD as compared to 
healthy age-matched controls.158  
Support to the diminished SOD defenses has been demonstrated by Belch et al159 
in 20 patients with PAD.  However, in their study GSH was elevated in the PAD patients 
compared to healthy age-matched controls. It should be noted that, enzymatic antioxidant 
testing in the study by Belch and colleagues159 focused on the red blood cell, which is 
different from that by Pipinos and colleagues97 which utilized biopsied gastrocnemius 
muscle and therefore may be more representative of the antioxidant deficiencies in PAD 
patients with claudication. 
Research by Langois and colleagues74 has shown that vitamin C levels as assessed 
by alkaline phosphatase activity in PAD are reduced compared to both healthy control 
subjects and non-PAD patients with hypertension.  This study adds evidence that high 
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oxidative stress associated with PAD, promotes the suppression of antioxidant defenses, 
which also is related to low grade inflammation.  Findings of the diminished vitamin C 
levels were independent of potential confounding variables including: hypertension, 
hyperlipidemia, gender, physical activity status, and anti-hypertensive drugs.  Lastly, 
Langois and colleagues74  showed that lower serum vitamin C levels were related to 
disease severity as assessed by ABI, MWD, and inflammation (CRP). 
In contrast to the above findings, Turton et al160 and Khaira et al83 reported that 
baseline levels of plasma TAC, measured by enhanced chemiluminescent assay 
(horseradish peroxidase), is similar in PAD patients in comparison to controls.  Khaira 
and colleagues83 suggest that this assay may be a superior method of testing antioxidant 
status compared to the assessment of individual antioxidants and cofactors as many exist 
and their relative importance may vary with different situations. Disparate baseline post-
ischemic exercise (via treadmill walking) findings were present between the two above 
studies.  Khaira et al83 found a significant post-exercise decrease in TAC in patients with 
PAD, while this biomarker increased post-exercise in healthy subjects.  These researchers 
concluded that the non-significant baseline findings may have been due to the small 
sample size (n=20), and would probably be abolished with an increase in study 
participants.83    However, Turton et al160 demonstrated post exercise TAC levels were 
slightly elevated in three separate assays taken at 5, 30, and 50 minutes post-exercise.  
Although these were non-significant findings, the TAC levels in those participants with 
claudication were higher than healthy control subjects measured at each of the time 
points.  Turton and colleagues160 also note that the TAC may not encompass the entire 
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picture of the antioxidant system.  Changes to the levels of the intercellular antioxidant 
enzymes are not reflected by the horseradish assay method, so antioxidant deficiencies 
may still exist in chronically ischemic skeletal muscle.97  For a summary of inflammation 
and oxidative stress levels in patients with claudication, refer to Table 1. 
Consequences of Chronic Inflammation and Oxidative Stress in patients with PAD 
Mitochondrial Dysfunction associated with PAD (summarized in Tables 2-4) 
Several researchers have postulated that chronic RONS exposure contributes to 
mitochondrial damage in patients with claudication,56,97,141,142,161-163 which makes this disease 
particularly troublesome, as this process may further lower oxygen delivery and its 
utilization.97,98 Damage to the mitochondria that results in deficiencies in ATP production 
has been dubbed in the literature as a form of mitochondrial myopathy,56,97 and has been 
listed as a comorbidity in several other diseases, including type 2 diabetes mellitus and 
renal failure.  Mitochondrial dysfunction is considered a disease of the mitochondria 
characterized because of the following: 1) slowed oxygen kinetics at the onset of 
exercise, 2) impaired oxidative phosphorylation, 3) lowered TCA activity, leading to the 
accumulation of acylcarnitines), and 4) lowered cellular respiration or decreased activity 
of the electron transport chain.   
Oxygen on-Kinetics with claudication 
Impaired oxygen on-kinetics, or a delay in the rate of change of oxygen uptake, is 
a cornerstone of several diseases that are characterized by the inability of the 
cardiopulmonary system or skeletal muscle to deliver or utilize oxygen.  Whole body 
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VO2 analysis during a constant workload, cardiopulmonary treadmill test has been 
utilized by researchers to demonstrate significantly slowed oxygen uptake kinetics in 
patients with claudication.164-166 Such constant load, low intensity protocols require the 
patient to achieve steady state oxygen consumption, be below their anaerobic threshold, 
and cannot be experiencing claudication.  Bauer et al164,167 failed to find a relationship 
between disease severity (ABI criterion) and VO2 on-kinetics leading the researchers to 
conclude that this was a reflection of altered skeletal muscle metabolism, independent of 
hemodynamic limitations that occur with claudication.  A follow-up study by the same 
group of researchers166 compared the VO2 on-kinetics during upper vs. lower body 
exercise with endothelial function as measured by vascular response to reactive 
hyperemia, and also gave support to local skeletal muscle dysfunction.  Compared to 
control subjects, VO2 on-kinetics were significantly prolonged during treadmill exercise 
in PAD patients, but not with arm exercise, and neither were correlated to measures of 
reactive hyperemia.  Since VO2 on-kinetics were not related to vascular reactivity, 
impaired cardiac or pulmonary function (exclusionary criteria), the researchers therefore 
concluded that local abnormalities distal to the arterial occlusion in the presence of PAD 
is likely a major contributing factor in the pathophysiology of the disease.   
The viewpoint of local skeletal muscle dysfunction as a major determinate of 
altered VO2 kinetics is not expressed by all investigators.  In agreement with previous 
studies164-166  Barker and colleagues168 did find impaired VO2 on-kinetics with onset of 
exercise in patients with claudication as compared to control subjects, and this delay in 
the PAD group was significantly negatively correlated to walking time (r=-0.72) and 
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peak VO2 (r=-0.66, P=0.05).  However the VO2 on-kinetics were significantly correlated 
with resting ABI (r =-0.63, P=0.05) in patients with claudication, which suggests that 
blood flow limitations are a causative factor.  In general, it is a universal finding of 
impaired VO2 kinetics in patients with claudication, however due to methodological 
limitations, researchers have come to disparate conclusions on whether this is caused by 
metabolic164,166 or hemodynamic deficiencies in PAD patients.168 Since blood flow was not 
directly analyzed during cardiopulmonary testing, the mechanism for these findings can 
only be speculative. 
Additional research from Bauer et al167 has attempted to alleviate the above 
limitation with the use of near infrared spectroscopy (NIRS) to assess blood flow and 
tissue oxygen saturation (StO2).  Using concurrent NIRS analysis the researchers 
demonstrated impaired oxygen extraction by the mitochondria during the initial during 
the initial phase of a constant workload cardiopulmonary treadmill test, indicative of a 
mitochondrial defect.  In patients with claudication, StO2 was slowed at the onset of 
exercise as compared to matched control subjects as indicated on the NIRS as a delay in 
hemoglobin desaturation.  These investigators postulate that the findings are consistent 
with a metabolic not hemodynamic limitation.  Their reasoning for the above conclusion 
is as followed:  if at the onset of exercise the delivery is limited by arterial disease, there 
should be a rapid desaturation of hemoglobin and myoglobin present in the muscle as 
oxygen is utilized, which was not found in this cohort.  In contrast, if the delivery is 
adequate to meet the initial demands of exercise, but muscle oxygen use is impaired, then 
hemoglobin desaturation would be delayed.  The assumption that the researchers are 
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making is based on the fact that at the onset of exercise, blood flow is not impaired, a 
finding in early research by Sorlie and Myhre.169 However, this viewpoint is not 
unanimously endorsed in the field today.   
Impaired Oxidative Phosphorylation in Patients with Claudication 
Phosphorus 31 magnetic resonance spectroscopy (31P MRS) is a non-invasive 
technique that allows for the continuous analysis of phosphorylated compounds involved 
in muscle energetics.170,171 This technique is used primarily for the analysis of oxidative 
phosphorylation primarily with the marker of phosphocreatine (PCr) and adenosine 
diphosphate (ADP) resynthesis, processes largely dependent upon aerobic metabolism.172  
31P MRS has been utilized frequently in claudication studies demonstrating delayed calf 
muscle PCr recovery after fatiguing isometric,173-175  isotonic, 98,170,176 and non-ischemic 
plantar flexion protocols. 173 All studies to date, covered in this review, all showed 
significantly impaired PCr recovery in patients with PAD compared to matched 
controls98,170,173-177 as well as only in the symptomatic leg of persons with unilateral PAD.176 
Support to the degree of large vessel stenosis causing impaired ATP production have 
been presented and are based on strong and significant correlations of PCr recovery to 
ABI or angiography readings.177 However, these correlations to hemodynamic parameters 
have not been a universal finding.98,170 Conclusions on the cause of the skeletal muscle 
dysfunction cannot be made in this population unless simultaneous measurements of 
blood flow are made, which is a limitation in some,170,173,176 but not all studies.98  In 
addition to the simultaneous measurement of tissue perfusion with PCr recovery, studies 
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which focus on such measurements pre and post vascularization have aided in the 
understanding of the pathophysiology of PAD.178  
Kemp and affiliates174 used a combination of NIRS and MRS in an attempt to 
differentiate hemodynamic and metabolic factors in the pathophysiology present in the 
altered oxidative phosphorylation capabilities in those with claudication.  In addition to 
finding impaired NIRS and PCr recovery after the performance of both 50% and 75% 
maximal voluntary contraction isometric exercise that was interpreted as a reflection in 
inadequate oxygen supply.  This was determined in particular by the data of NIRS 
recovery, which was interpreted as the oxygen use outpacing the delivery.  As with the 
mechanisms leading to impaired oxygen kinetics with exercise, conflicting evidence with 
PCr recovery exists.  Anderson and colleagues,98 in an elegant study, incorporated a 
protocol that simultaneously measured atherosclerotic plaque burden, tissue perfusion 
with MRI, and PCr recovery after maximal isotonic plantar flexion exercise.  The 
researchers found that the severity of macrovascular obstruction, plaque burden, tissue 
perfusion, and aerobic metabolism parameters all relate to the functional impairments in 
PAD.  However the most important findings giving credence to impaired aerobic 
metabolism, independent of hemodynamic parameters, was that PCr recovery was 
uncoupled from tissue perfusion (tissue blood flow in calf corrected for arterial inflow, 
thereby measuring microvascular perfusion).   
Support for impaired skeletal muscle bioenergetics before and after 
revascularization has been demonstrated in patients with claudication in studies by Zatina 
et al178 and West et al.179 In the former, all participants with claudication (ABI ranges 0.4-
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0.9) showed prolonged PCr recovery after isotonic plantar flexion exercise, but more 
importantly those with severe ischemia (ABI≤ 0.4) were also shown to have prolonged 
PCr recovery rates before and after revascularization and did not improve until several 
months after surgery. This finding suggests that in severe ischemia, impaired oxidative 
phosphorylation may be due to mitochondria dysfunction independent of altered 
hemodynamics associated with PAD.  In contrast, a recently published pilot study by 
West and colleagues179 did find significant improvement in PCr recovery after 
percutaneous lower extremity revascularization in ten patients with claudication 
(although not to the degree of healthy, age and sex-matched controls).  Although certain 
limitations existed, primarily in subject number and certain endpoints were 
underpowered, revascularization and subsequent PCr recovery did not alter tissue 
perfusion or improve exercise parameters such as 6 minute walk test, maximal walking 
distance on graded exercise test and peak oxygen consumptions.  West and colleagues179 
hypothesized that with large vessel revascularization, bulk blood flow to the calf 
improves, which can alter post exercise PCr recovery primarily through positive 
influences of shear stress on endothelial functioning. 
Enzyme activity analyses in claudication 
Analyses of muscle enzyme content and activity in patients with PAD have 
produced heterogeneous results; however, muscle biopsy of the calf muscle has helped in 
the elucidation of the etiology of PAD.  This invasive technique allows measurements to 
be performed in a controlled setting, and more importantly, negates the confounding 
factor of blood flow, a limitation in many techniques.  Factors that directly influence 
33!
oxidative phosphorylation independent of blood flow include mitochondrial density and 
enzymatic function of the electron transport chain within the mitochondria, and substrate 
availability resulting in the generation of NADH and FADH2.   
It is a common finding that mitochondrial content per unit of muscle as assessed 
by mitochondrial DNA content,141 non-collagen protein,161 citrate synthase,56,95,180-184 and 
cytochrome c oxidase,95,141,184 does not differ or may be slightly elevated in those with 
claudication compared to healthy control subjects.  However, this may not be true in 
patients with critical limb ischemia (ABI ≤ 0.4),185 as both citrate synthase and 
cytochrome c oxidase levels are suppressed compared to healthy individuals.97,184 In 
addition, findings by Pipinos et al,161 show that mitochondrial content per gram of wet 
weight muscle as demonstrated by citrate synthase and cytochrome c oxidase are strongly 
related to VO2 peak in healthy controls, but not in PAD participants, which further 
suggests that the density of mitochondria in the ischemic skeletal muscle may not the 
problem. With lack of substrate availability56,96,180,186 and low mitochondrial density being 
unlikely,56,95,97,141,180-182 impaired cellular metabolism downstream of glycolytic and B-
oxidation pathways, such as enzyme activity within the pyruvate dehydrogenase complex 
(PDCa), TCA cycle and electron transport chain, may be implicated in the etiology of 
claudication. 
PAD metabolic abnormalities, particularly in the sedentary patient with PAD, 
may start with deficiencies in PDCa which have been postulated by several researchers.186 
Hou and colleagues186 showed that gastrocnemius muscle from trained eight PAD 
individuals showed an increased ability to oxidize CHO substrate, such as pyruvate and 
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malate compared to gastrocnemius muscle from seven untrained PAD patients and eleven 
healthy control subjects.  However, the metabolism of esterified fatty acid substrate 
palmitoyl-L-carnitine (by the biopsied gastrocnemius) was similar in control subjects and 
those with PAD regardless of training status.  This suggests that carbohydrate metabolism 
and the rate of PDCa may be of importance in providing flux through the TCA cycle. It is 
important to note that these results may also show the importance of exercise, which is 
discussed later in this review.  Additional support to unaltered fatty acid oxidation is 
provided by Lundgren et al,180 who showed that the activity of the B-oxidation enzyme, 3-
hydroxyacyl-coA dehydrogenase is similar between patients with PAD and healthy 
controls subjects.  Barker and colleagues,168 in addition to measuring VO2 on-kinetics, 
directly measured the activity of PDCa for deficiencies in carbohydrate oxidation.  
Although PDCa was not significantly lower in patients with PAD compared to matched 
control subjects, activity was significantly correlated to VO2 on-kinetics, a variable that 
inversely correlates with MWD and functional capacity.  This shows that although 
carbohydrate metabolism is not significantly inhibited, those with lower PDCa will likely 
have diminished exercise capacity, which may be improved with aerobic exercise 
training.   
The culmination of fatty acid and glucose metabolism is acetyl CoA, a 2 carbon 
intermediate that enters the TCA cycle for subsequent oxidation to CO2 and H2O, and 
byproducts NADH and FADH2, the fuel for the electron transport chain.  Hiatt et al,96,187-189 
have demonstrated that patients with claudication often have increased levels of 
acylcarnitines, suggestive of compromised aerobic metabolism due to decreased TCA 
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cycle intermediate concentration or enzyme activity.  Adams summarizes the process and 
provides a hypothetical paradigm by suggesting that there is 1) an inadequate capacity for 
the TCA cycle relative to fuel delivery due in part to reduced anaplerotic propionyl CoA 
pools (reflected in lower propionylcarnitine levels and, 2) a mismatched acetyl CoA 
generation vs. entry into the TCA cycle leading to increased accumulation of acetyl CoA.  
In the former, it is hypothesized that inadequate substrate produced in pleiotropic 
pathways such as propionyl CoA (reflected in reduced propionylcarnitine levels can slow 
down TCA activity.  However this may also reflect an enzymatic problem of propionyl 
CoA carboxylase or methylmalonyl-CoA mutase, and may be a likely source of the 
problem as amino acids can be used in the generation of propionyl CoA.190 Additionally, 
free radical induced suppression of enzyme activity, particularly of key regulatory steps 
such as citrate synthase, isocitrate dehydrogenase, and α ketogluterate dehydrogenase can 
depress the overall activity of the cycle and subsequent production of NADH and 
FADH2.191 As a result of the inhibition of the TCA cycle and the accumulation of acetyl 
CoA, negative feedback loops would suppress activity of enzymes involved in the 
allosteric regulation of carbohydrate and fatty acid metabolism including; PDCa, 
pyruvate kinase, and thiolase.  The formation of acylcarnitines, often referred to also as 
the “buffering” of acetyl CoA by carnitine, is an attempt to maintain metabolic 
homeostasis through the prevention of acetyl CoA build up and subsequent pathway 
inhibitions.  Although acylcarnitine levels are an indicator of an altered metabolic state, 
this marker has been significantly higher in some,56,96,187 but not all cohorts168 with 
claudication compared to matched control subjects. In a major study by Hiatt et al96 PAD 
patients with the greatest accumulation of acylcarnitines, particularly in those with 
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unilateral disease, had poorer treadmill performance, and this accumulation of 
acylcarnitines in the skeletal muscle was a greater predictor of walking performance in 
comparison to hemodynamic measures such as ABI.  
In addition to the proposed dysfunction of the TCA cycle, aberrant mitochondrial 
functioning within the electron transport chain may also slow ATP production and 
additionally promote the generation of ROS that may result in enzymatic inactivation and 
mtDNA oxidation.  Brass and colleagues95 demonstrated a link between impaired ATP 
synthesis and diminished mitochondrial respiration in seventeen patients with 
claudication.  Using biopsied muscle from the gastrocnemius and substrates to the ETC, 
it was found that NADH dehydrogenase (a proximal enzyme in complex I of the ETC) 
activity was 27% and 26% lower in PAD patients compared to that of biopsied 
gastrocnemius muscle excised from nine age-matched control subjects when normalized 
per citrate synthase and cytochrome c oxidase respectively.95 Additionally, when 
expressed per unit of cytochrome c oxidase, activity of ubiquinol cytochrome c 
oxidoreductase was decreased by 38% in PAD patients in comparison to the healthy 
control subjects.95 Similar findings have been documented by Pipinos et al,97 in PAD 
patients as both mitochondrial complex I & III activity and respiration are significantly 
lower compared to matched control subjects when normalized per citrate synthase.  An 
additional and novel finding from the study by Pipinos and colleagues97 was that complex 
IV (cytochrome c oxidoreductase) also showed a significant reduction in activity.  The 
diminished activity of complexes I, III, and IV will lead to a diminished transfer of 
electrons resulting in a decrease in the quantity of protons pumped from the 
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mitochondrial matrix into the inner membrane.  The proton gradient and pumping of 
protons back through ATP synthase into the matrix is the catalyst of oxidative 
phosphorylation.  A reduced flow of protons across the proton gradient due to a lower 
complex activity will directly hamper oxidative energy production.192 
Not only does the dysfunctional ETC cause diminished energy production, the 
leakage of electrons from the complexes will oxidize oxygen in the mitochondria leading 
to superoxide production.122  O2- that evades dismutation via mitochondrial SOD will 
directly cause damage to the electron transport change via oxidation.122 Increased 
oxidative-induced damage to complexes I, III, and IV will cause both a diminished flow 
of electrons leading to further impaired energy production, and an increased generation of 
O2-.  This positive feedback loop also further intensifies mitochondrial dysfunction.  
Furthermore, the autocrine action of O2- can damage mtDNA, which is highly susceptible 
to injury due to its close proximity to the electron transport chain.  The belief is that 
repetitive mtDNA damage due to chronic oxidative stress may result in deletion, 
particularly a 4977-base pair deletion spanning mtDNA nucleotide pairs 8469 to 
13477.122,141,142 Deletions in the mtDNA genome would likely impair the ability of the cell 
to repair the damaged enzyme complexes caused by repetitive oxidative stress and 
accelerate O2- production leading to or exaccerbating mitochondrial dysfunction.  Bhat 
and colleagues141 indeed found mtDNA deletion in those with PAD vs. healthy aged-
matched control subjects (0.88% vs. 0.43%).  Although the difference was significant 
between groups, the researchers concluded that due to the very low percentage of 
deletions that constitute the entire mtDNA genome, the absolute number of mtDNA 
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deletions makes little difference in regards to mitochondrial dysfunction.   Brass et al142 
also investigated the same mtDNA deletion pattern in conditions of unilateral PAD.  
Although a large number of deletions were found in the biopsied gastrocnemius samples, 
the deletions were not limited to the symptomatic limb.  The findings led the researchers 
to conclude that since the mtDNA deletions were not limited to the ischemic limb, they 
are unlikely to contribute to the pathophysiology of PAD.142 
Conclusions from mitochondrial dysfunction studies in PAD 
1. Rates of glycolytic (PFK, LDH) and beta oxidation (3-hydroxyacyl CoA 
dehydrogenase) enzymes appear to be similar at rest between patients with 
claudication and healthy age-matched controls.  However aerobic treadmill 
training appears to upregulate the glycolytic enzymes, but not those involved in 
beta oxidation.   
2. Build-up of acylcarnitines at rest and after exercise demonstrates a decrease in 
flux of acetyl-coA entering the TCA cycle.  This has the potential to decrease the 
amount of NADH and FADH2 available to enter the electron transport chain for 
ATP production. 
3. Impaired bioenergetics are evident in those with PAD as evidenced by impaired 
PCr recovery after exercise suggesting deficient oxidative metabolism. 
4. A chronic deficiency of oxygenated blood to the ischemic skeletal muscle is the 
one of the drivers behind the development of dysfunctional mitochondria or 
mitochondrial inertia. 
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5. Despite normal markers of mitochondrial content in claudicating muscle as 
evidenced by citrate synthase and cytochrome c oxidase dysfunction still exists. 
6. The electron transport chain is a main site of cellular dysfunction as mitochondrial 
respiration is hindered particularly at complexes I, III, and IV.  The loss of 
electrons and diminished proton gradients reduce the amount of protons entering 
complex V (ATP synthase), which leads to reduced ATP production.  The 
reduced ATP production by ATP synthase will lead to the diminished oxidative 
driven recovery of PCr. 
7. As a result of electron loss during accelerated mitochondrial respiration, a higher 
generation of O2- is produced as oxygen accepts these electrons. 
8. Additional sources of O2- such as NADPH oxidase due to inflammatory induced 
neutrophil attraction, adhesion, transmigration, and endothelial activation may 
occur.  XO, also generated in conditions of ischemia and subsequent reperfusion, 
is also a likely major factor in O2- generation during bouts of claudication. 
9. O2- released from a “leaky” or dysfunctional mitochondria will act in an autocrine 
manner and further damage mtDNA and complexes I, III, and IV of the electron 
transport chain.  This has to potential to limit complex repair that may ultimately 
lead to a feed forward cycle of complex damage and O2- production.  Although 
damage to mtDNA is significant, it is relatively small in terms of the overall 
mtDNA genome. 
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10. O2- may be dismutated to H2O2 by the mitochondrial antioxidant MnSOD.  H2O2 
is membrane permeable and can enter the cytoplasm where it may be converted to 
OH- in the presence of a metal catalyst such as Fe.  OH- can cause further damage 
to the cell membrane of the mitochondria, making it more susceptible to damage. 
11. Endogenous antioxidants, particularly MnSOD are deficient in PAD, which 
largely protect the mitochondria from O2- induced damage.  An impaired 
antioxidant system promotes a cellular pro-oxidant state and likely promotes 
further cellular dysfunction. 
Endothelial Dysfunction and PAD 
The vascular endothelium is the inner layer of cells that line the blood vessels of 
our circulatory and lymphatic system.  Endothelial cells play a major role in vascular 
biology as key regulators of blood flow via autocrine, paracrine, and hormonal-like 
mechanisms by the control of endothelial derived relaxing factors (EDRF) nitric oxide 
(NO) and prostacyclin (PGI2) and vasoconstrictors; endothelin (ET-1) and thromboxane 
(TXA2).  In addition to the control of dilation and constriction, endothelial cells are major 
regulators of vascular homeostasis through the following mechanisms; maintenance of 
vascular tone, prevention of vascular smooth muscle proliferation, reduction in leukocyte 
adhesion and activation, inhibition of platelet aggregation, and thrombus formation.73   
All of the aforementioned risk factors are implemented in the development and evolution 
of atherosclerotic plaques that ultimately lead to the development and progression of 
PAD and may be caused by chronic inflammation and oxidative stress.   
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Endothelial dysfunction73,75,79,193 is one component of the pathophysiology of PAD 
and is associated with its disease severity72,79 cardiovascular risk,194-196 and exercise-
induced claudication.  Several biomarkers exist such as vonWillenbrand factor (vWF), 
ADMA, cellular adhesion molecules (CAMS), and selectins, which are commonly used 
to indicate endothelial dysfunction in patients with claudication, however, these are not 
universally agreed upon.  Tests of post occlusive reactive hyperemia using strain gauge 
plethysmography or flow mediated dilation (FMD) techniques represent endothelial 
dependent vasodilation offer support to dysfunctional endothelium, a trademark of 
PAD.197  Tests of post occlusive reactive hyperemia and even maximal hyperemia 
(exercise plus arterial occlusion) also prove valuable in the assessment of the therapeutic 
interventions such as exercise.198,199   Although strain gauge plethysmography can assess 
hyperemic flow to both the forearm and calf, FMD is limited to the use of endothelial 
function in the brachial artery, but is still the gold standard in the systemic assessment of 
vascular reactivity.200  The following is a brief depiction of the roles of inflammation and 
oxidative stress in the development of endothelial dysfunction. 
In the healthy endothelium, the amino acid L-arginine and cofactor BH4 are 
converted to NO and L-citrulline in a reaction catalyzed by eNOS,156,201 in response to 
receptor agonists such as bradykinin, adenosine, acetylcholine, and physiological stimuli 
such as laminar shear stress.202 The resulting NO can diffuse to the adjacent smooth 
muscle where it promotes the G-protein-mediated activation of a membrane-bound 
guanylate cyclase (GC),203  the formation of second messenger cGMP,204 and subsequent 
activation of a cGMP dependent protein kinase.204 The activation of the of cGMP and 
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protein kinase promotes the opening of calcium dependent potassium channels thereby 
inducing a state of membrane hyperpolarization in the smooth muscle cell and thereby 
the inhibition of cytosolic calcium influx and reuptake of calcium into the sarcoplasmic 
reticulum.   The regulation of calcium is therefore essential in maintenance of vascular 
tone and contractile activity in smooth muscle.  Free calcium in the cytosol binds to a 
calcium-binding protein (i.e. calmodulin), an interaction that activates myosin light chain 
kinase, an enzyme that is capable of phosphorylating myosin light chains in the presence 
of ATP.205 Myosin light chain phosphorylation leads to cross-bridge formation between 
the myosin heads and the actin filaments and hence, smooth muscle contraction.205 The 
aforementioned process of smooth muscle vasoconstriction, is a normal physiological 
process, but may become pathological in chronic presence of chemical stimuli such as 
AII, TXA2, ET-1, norepinephrine, and vasopressin.  Each of these chemical stimuli will 
act on signal transduction pathways that culminate in the release of calcium.  As 
mentioned above, the removal of calcium from the cytosol, activation of the second 
messengers metabolites (i.e. cAMP, cGMP) by vasodilatory agents (NO, PGI2) and 
stimulation of myosin phosphatase (all essential in calcium regulation) initiate the 
process of smooth muscle relaxation. 
Endothelial dysfunction is described and characterized by the decrease in 
production and bioavailability of NO by the endothelium that predisposes the artery to 
conditions of vasoconstriction and thrombosis.206   The reduction in the bioavailability of 
NO with endothelial dysfunction cannot be attributed to one single factor; in fact it may 
be due to several contributors73 such as decreased eNOS expression, insufficient L-
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arginine207 or BH4,208,209 presence of eNOS antagonists such as ADMA,210-215  and 
increased degradation of NO.125 Other potential causes that may affect NO bioavailability 
include decreased DDAH (catalyst for ADMA degradation),210,216 increased arginase,217 
and the uncoupling of eNOS and GC.218-220 Munzel et al states that endothelial dysfunction 
is largely due to an increased production of reactive oxygen species such as O2-, which 
leads to the reduction in the vascular bioavailability of NO.125   Support to this claim is 
provided by Ohara and colleagues126 who conclude that in pathogenic conditions, the 
vascular endothelium is a potent source of O2- that can inactivate eNOS.   RONS are a 
culprit in the cellular maladaptations, such as the inhibition of DDAH and uncoupling of 
eNOS, GC, and BH4, which suggests that RONS may be considered a major cause of 
endothelial dysfunction.127,210,218,219,221  
Protection from RONS is provided by endogenous antioxidants, however this 
protective effect may be inefficient as O2- reacts with NO at a rate 3 times as fast as the 
dismutation reaction catalyzed by SOD.214   The reaction of O2- and NO yields ONOO-,222 
and therefore diminishes the short term bioavailability of NO,223 potentially lowering 
arterial dilatory capabilities and protection for atherogenic stimuli.  Additionally the 
chronic production of ONOO- can have serious consequences that lead to the 
development of endothelial dysfunction.  Although ONOO- has been implicated in the 
oxidation of DNA and lipids,222 this RNS has direct effects on the dilatory capabilities of 
the artery.   
Chronic ONOO- formation can lead to endothelial dysfunction via several 
mechanisms on BH4 and eNOS itself.  BH4 is essential for eNOS functioning as it 
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stabilizes the enzyme and increases the affinity of eNOS to the substrate L-arginine.  
ONOO- has been shown to directly oxidize BH4 to the non-eNOS cofactor BH2.219,224   
Without this cofactor in its reduced form, NO production is extremely limited, and the 
uncoupling of eNOS ensues.224  This has been demonstrated by Zou and colleagues220 as 
RNS directly oxidize the zinc-sulfur clusters present in the eNOS enzyme.   Uncoupled 
eNOS will now generate O2- rather than NO, leading to a twofold problem of increased 
oxidative stress to the cell, and the exacerbation of the NO deficiency. ONOO- not only 
effects the endothelium, it also has damaging consequences in the vascular smooth 
muscle.218   In the healthy endothelium, NO is released and binds to the smooth muscle 
surrounding the blood vessel activating GC and through signal transduction, inhibits the 
release of calcium into the cytosol therby promoting smooth muscle cell relaxation and 
therefore vasodilation.203   GC is inhibited by ONOO-, which leads to a disruption in the 
signal transduction pathway where the relaxation message carried by NO is not received 
by the smooth muscle.218  
In addition to its inactivation of eNOS, ONOO- is a radical that is very capable in 
damaging the cell structures that may come in contact with.  Similar to the OH-, ONOO- 
may initiate lipid peroxidation that is devastating to the endothelial membrane through an 
event known as arachadonic acid cascade characterized by the acute formation of 
eicosanoids.211  It is believed that ischemia, ONOO- and OH- are potent activators of 
phospholipase A2 (PLA2), an enzyme that cleaves arachadonic acid from the cell 
membrane, which initiates the release of arachadonic acid from the membrane.225  
Arachadonic acid can be metabolized by several enzymes, most notably prostaglandin 
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endoperoxidase cyclase or COX and LOO, which as previously mentioned are two more 
contributors to O- production.  The COX and LOO reactions yield eicosanoids 
(prostacyclins, prostaglandins, thromboxanes, and leukotrienes), which have various 
effects on the vasculature.   Most notably TXA2 and leukotriene C4 (LTC4) contract 
smooth muscle, while TXA2 induces platelets to adhere to one another in an event 
referred to as platelet aggregation.  Furthermore these arachadonic acid metabolites 
further contribute to the inflammatory state induced by ischemia by increasing capillary 
permeability, leukocyte infiltration, and the production of RONS during their synthesis 
via LOO and COX. 
Inflammation may also result in endothelial desquamation, resulting in the loss of 
functional endothelium, and thereby reducing eNOS concentration and overall activity 
within the endothelium.18  This process of desquamation may be the result of apoptosis, 
which is often regulated or promoted by chronic elevation of proinflammatory cytokines 
such as TNFœ.81   Additionally inflammatory mediators and oxLDL can stimulate the 
expression and activation of matrix metalloproteinases specialized in degrading 
components of the subendothelial basement membrane.18 
Therapeutic Effects of Exercise:  Mechanisms Pertaining to Inflammation, 
Oxidative Stress, Antioxidant Capacity, Mitochondrial and Endothelial 
Dysfunctions  
Aerobic Exercise & Indices of Inflammation in Patients with PAD 
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As discussed earlier, ischemia-inducing exercise may induce a state of 
inflammation, augmenting neutrophil-endothelial adhesion and endothelial 
activation,61,160 microalbuminuria,112 and ROS generation, and therefore promote 
endothelial dysfunction and atherosclerosis.  Early research on this topic focused on the 
effects of acute treadmill exercise in patients with claudication, with several studies 
showing a resulting condition of post exercise neutrophilia.61,160,226 Turton et al226 showed 
that in individuals with PAD that walked to their maximal levels of claudication, showed 
both neutrophilia and a significant rise in CD11b expression compared to healthy age-
matched control subjects.  Later (in a different study), Turton and colleagues160 found that 
after an acute bout of exercise, untrained participants with PAD experienced a significant 
66% increase in activated neutrophils (CD-18b) and this change was significant 
compared to age-matched control subjects.   However, this inflammatory effect of acute 
exercise was abolished following the completion of 3 months of supervised exercise 
involving a combination of static and treadmill training.160   Likewise, Nawaz et al61 found 
significant increases in activated neutrophils (CD11-b & CD66-b) after an acute bout of 
treadmill exercise before and after 6 weeks of training among 3 groups (treadmill, arm-
ergometry and standard of care).  However the group randomized to arm-ergometry had 
the lowest levels of activated neutrophils following treadmill exercise after 6 weeks of 
training.  (Studies regarding the inflammatory response to acute exercise in patients with 
PAD are summarized in TABLES 5 & 6). 
The above findings suggest that acute bouts of exercise that induces ischemia may 
exacerbate systemic markers of inflammation and oxidative stress (in the short-term), but 
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this response may be alleviated with prolonged endurance training.   This response may 
be mediated by an IPC mechanism as discussed by Capecchi et al51as repeated 
submaximal, ischemia-inducing walking exercise improved PFWD and MWD in patients 
of PAD.  Furthermore this effect was evident in a very short training intervention (1-7 
days), which suggests a rapidly acting physiological mechanism.  The augmented 
toleration to exercise was also associated with a decrease in neutrophil reactivity and 
therefore a decrease in ROS generation (likely from NADPH oxidase).51 Lastly, the 
researchers also documented an increase in adenosine levels (from blood immediately 
drawn at the end of the symptom-limited treadmill test), which was ameliorated with 1 
week of training.51 The initial rise in adenosine was attributed to an internal mechanism 
to protect cells from I/RI, and the lower adenosine levels after training may represent a 
reduced requirement for the cell protective metabolite or IPC.51 It should be mentioned 
that the accumulation of the metabolite adenosine suggests an energy deficient state 
resulting in the upregulation of rate limiting enzymes of several metabolic enzymes and 
is also a potent stimulus for eNOS.  These results were in contrast to findings by Saxton 
et al,52 who did not find any change in heat-shock protein 70 (HSP70), a surrogate 
biomarker for IPC, in PAD patients undergoing upper or lower body ergometry training.   
Several researchers have investigated the effects of exercise training on 
inflammatory biomarkers, and neutrophils in PAD,52,61,158,160,227 which are summarized in 
Table 7.   Biomarkers of inflammation pre and post exercise intervention in patients with 
PAD have produced disparate results. This may be due to several factors, which include; 
differences in exercise prescription (frequency, intensity, duration, and type), timing of 
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blood extraction, and length of the intervention protocol, all of which make it difficult to 
compare results of studies.  Studies by Nawaz et al61 (n=52) and Saxton et al52 (n=92) 
have both found that neither 6 nor 24 weeks of arm ergometry or leg ergometry 
significantly lowered E-Selectin levels in patients with claudication, which was in 
contrast to an 8 week treadmill training intervention by Saetre and colleagues.227  In 
addition Saetre and colleagues227 (n=29) also found significant reductions in ICAM-1, 
which was not a significant finding by Saxton et al.52  Lastly, sVCAM did not change 
significantly in either study after exercise intervention.52,227  
Although the findings in these studies are disparate, it may be due to different 
biomarkers used, and suggests that additional research is needed to elucidate a potential 
IPC mechanism associated with treadmill training in PAD patients.  Taken together, the 
failure for treadmill training to significantly exacerbate inflammatory biomarkers227-229 
and the potential for IPC51 (although not conclusive), likely alleviates any concern that 
ischemia-inducing treadmill training is detrimental to endothelial and skeletal muscle 
health, and further progresses atherosclerosis.  However, the full anti-inflammatory 
effects of exercise training in this population are not yet well understood. 
Exercise as an Antioxidant  
Several variables exist in factoring the antioxidant capabilities of skeletal muscle, 
such as muscle fiber type, altered blood flow, and energy status.230 Several researchers 
have demonstrated that the specific activities of SOD, catalase, and GPX are greater in 
skeletal muscles composed primarily of oxidative fiber types of both sedentary and 
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exercise-trained rats.231,232 Both slow-twitch oxidative (soleus) and fast-twitch oxidative 
(red gastrocnemius) have greater antioxidant enzyme activity than type II glycolytic 
(white gastrocnemius) muscle fibers.231   
As mentioned previously, there is growing evidence that the continued presence 
of a low concentration of RONS is necessary to induce the expression of antioxidant 
enzyme.  This is explained by the concept of hormesis, which describes a state of eustress 
after low exposure to a toxin (in this case RONS), however this may turn to damage, if 
the exposure is high.34 Chronic exercise training appears to be important in the regulation 
of oxidative stress in healthy individuals, likely through the concept of hormesis.34 
Skeletal muscle antioxidant enzyme adaptations to exercise training appear highly tissue-
and muscle fiber-specific, and are dependent on training variables such as overall volume 
and session duration.232,233 The following is a brief review of studies investigating the 
effects of endurance training on the effects of individual endogenous antioxidants (in 
non-ischemic populations). 
In general, a majority of the studies investigating the chronic effects of exercise 
involved rats and can be considered high duration, high volume protocols, with 
differences existing in intensity.231,232,234-237 SOD has been shown to increase in a majority 
of the reviewed studies,232,234-236 but not in all.231 Increases in SOD activity have been 
limited to oxidative fibers such as the soleus (type I)232,234,236,237 and deep vastus lateralis 
(type IIa),234,235 while superficial vastus lateralis (type IIb) fibers have not experienced 
these adaptations.232,234 Powers and colleagues232 have shown that SOD levels were 
increased in the soleus muscle, but this was only found in the high intensity, high 
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duration group (75%VO2 max, 90 minutes per session).  This finding was in agreement 
with previous research by the same group of investigators, who found that both high and 
moderate intensity significantly increased SOD in the myocardium.236 However, Laughlin 
et al failed to find that 12 weeks of aerobic endurance treadmill training (2 hours/session) 
alters SOD activity in rats.231 Concurrent findings in each of the aforementioned studies 
were that levels of citrate synthase activity increased (a well-known mitochondrial 
adaption to endurance training), and that these increases were in excess to those of 
antioxidant enzyme activity adaptations.231,232,236   
Similar training endurance training adaptations are present for GPX as compared 
to SOD.  Increases in GPX activity have been shown in the soleus by both Criswell et 
al237 and Laughlin et al,231 but not in other studies.232,234 However a majority of the 
research suggests that type IIa fiber types may be the source of the enzymatic adaptations 
as all reviewed studies showed significant increases in GPX activity following endurance 
training.231,232,234,235,237 Furthermore manipulation of training variables may have an effect on 
the extent of these cellular adaptations.  Criswell et al237 found that 5 minute bouts of 
interval training (80-95% VO2 max) was superior to 45 minutes of continuous, moderate 
intensity (70% VO2 max), aerobic exercise for improving GPX activity.  This 
improvement was also greater compared to SOD, which was significantly elevated in 
both training groups.  Powers and colleagues232 also showed that exercise durations in 
excess of 60 minutes significantly increased GPX levels, with high (75% VO2 max) and 
moderate (65% VO2 max) intensities to a greater extent than low (55% VO2 max) 
intensity, although it may be argued the definition of high intensity in the latter study. 
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Another common finding in the literature is that catalase activity seems to remain 
unaltered after endurance training231,232,236 regardless of muscle type, although this finding 
is not universal.234 
Exercise does appear to be an adequate tool to counter free radical-induced 
oxidative stress, as RONS are the main promoters of antioxidant upregulation 
(hormesis).34,238 Discrepancies between studies particularly in animal age, assay methods, 
and exercise variables do make comparisons challenging.234 However, all reviewed 
methodologies used 5 day/week treadmill protocols with exercise durations ranging from 
1-2 hours, which may be considered high volume and high duration, but make 
comparisons between studies easier.  For exercise to be effective at upregulating 
antioxidant enzyme activity, special emphasis must be put on exercise prescription as it is 
apparent that sufficient intensity, volume, and duration of activity are essential for 
optimal adaptations.  Exercise prescriptions, particularly that of moderate to high 
intensity (75% VO2 or greater), and of sufficient duration 60-90 minutes appear to be 
optimal for GPX and SOD upregulation.  Furthermore antioxidant enzyme upregulation 
appears to be tissue and muscle fiber specific.  Only oxidative (type I and type IIa) fiber 
types, which are primarily recruited during moderate intensity aerobic exercise, 
experience an increase in antioxidant activity, while this is not observed in higher 
threshold muscle fibers such as type IIb.231,232,235-237,239,240 However, Ji et al33,230 cautions that 
although chronic higher volume and duration endurance exercise may be optimal for up 
regulation of antioxidant enzymes, it may decrease intracellular vitamin antioxidant 
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stores, with the potential to decrease the overall protective abilities of the cell and make 
the muscle more susceptible to oxidative stress. 
Research is lacking in regards to the effects of aerobic exercise training on 
enzymatic antioxidant adaptations in PAD populations, likely because of the risk 
associated with the biopsy of lower extremity skeletal muscle in this population.  As 
mentioned previously in this review, antioxidant enzyme activity (SOD, and GPX)97 and 
serum ascorbic acid levels74 are highly diminished in patients with claudication, which 
makes research regarding exercise and antioxidant enzymatic adaptations of significant 
importance.  However, exercise duration and intensity are limited during treadmill 
training in this population due to the presence of claudication, and it is known that both 
variables are important in antioxidant enzyme upregulation (as discussed above).  It may 
be that I/RI and the build-up of RONS are the stimuli for upregulation of these enzymes, 
but the chronic pro-oxidative state may overwhelm the antioxidant capacity of the 
skeletal muscle in the PAD population.    
Although the effects of exercise training on systemic biomarkers of oxidative 
stress in patients with PAD is lacking, there have been several randomized trials 
investigating the effects of exercise training on systemic isoprostanes.  These studies 
suggest that exercise may strongly reduce F2 isoprostanes among young women,241-243 
whereas this beneficial effect may be attenuated among older individuals and those with 
dyslipidemic, non-insulin depedent diabetes mellitus.244,245  All of these studies noted 
similar reductions in body mass and increased aerobic fitness following exercise 
intervention, despite wide ranges of intervention periods (8 to 52 weeks) and age groups 
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studied.  Campbell et al245 concluded that the gains in aerobic fitness (assessed by VO2 
peak) improve oxidative stress levels, probably because of exercise-induced adaptations 
of the antioxidant defense system, and that the effect occurs independent of general or 
abdominal adiposity. 
Aerobic Exercise and Skeletal Muscle Metabolic Parameters in PAD 
Exercise training results in numerous biochemical and physiological adaptations 
within the skeletal muscle in both healthy and diseased persons.  One major adaptation is 
the increased utilization of fatty acids and sparing of muscle glycogen and blood glucose 
as fuel sources.246,247 This improved “economy” is partially the result of mitochondrial 
adaptations, as aerobic exercise is also a well-known stimulus for enhanced 
mitochondrial biogenesis and elevated function of individual mitochondrial enzymes.248 
Improvements in aerobic metabolism may result in a delay in onset of blood lactate 
accumulation and removal of lactic acid, which may be important particularly for patients 
with claudication.  Although plausible, this has yet to be shown in “high quality” studies 
involving patients with symptomatic PAD, likely because many PAD patients do not 
reach their lactate threshold during treadmill exercise before claudication leads to 
exercise termination.   
A majority of metabolic adaptations to exercise training in patients with 
claudication have focused on products of metabolism such as carbon dioxide and lactate 
during exercise testing, 6,249,250 utilization of acylcarnitines,56,251 and alterations in 
mitochondrial uptake of oxygen (a-VO2 difference)249 as indirect indices of improved 
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mitochondrial functioning.  Although the results of exercise training on aerobic 
metabolism parameters such as PCr recovery using MRS methods have yet to be utilized, 
analyses of aerobic and glycolytic enzymes have yielded results in support of the belief 
that lower extremity exercise training alters skeletal muscle metabolism in patients with 
PAD.  However, it also should be noted that a major limitation in reviewing literature on 
the effects of exercise training on enzymatic activity from biopsied skeletal muscle from 
PAD patients involves subject numbers and characteristics.  Several of the studies that are 
subsequently discussed are limited by low subject number and homogenicity, small 
inclusionary criteria, and poor external validity, and as a result, may lead to inconclusive 
findings. 
Indirect measures of oxidative metabolism in patients with claudication, measured 
by lactate concentration and respiratory exchange ratio (RER) during constant load 
treadmill testing, have shown positive adapations in response to prolonged treadmill 
exercise training.6,252 Reductions in RER and lactate production after treadmill training 
were superior compared to PAD patients randomized to strength training as well as non-
exercise control gropus.6 Research by Sorlie and Myhre249 also demonstrated a 26% 
increase in exercise capacity in participants with PAD that participated in 3 to 4 months 
of aerobic exercise training.  In addition to reductions in lactate production or 
accumulation, improvements in aerobic metabolism were attributed to lower popliteal-
venous oxygen saturation at exhaustion, suggestive of increased oxygen extraction.   
Although a-vO2 difference may represent increased oxygen extraction and utilization, this 
may be a result of increased capillary density, a hemodynamic variable that is suggestive 
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of enhanced oxygen delivery and diffusion to the mitochondria.248 Recently, research by 
Duscha et al253 showed that aerobic exercise training increased capillary density in 35 
patients with claudication, and this improvement precedes increases in VO2 peak.  
Although certain limitations exist in the analysis of improved a-VO2 difference, as 
suggested above, muscle biopsy studies have aided in the understanding of metabolic 
adaptations to exercise. 
Mixed evidence exists in the effects of exercise training on mitochondrial 
biogenesis, as some studies, but not all56,254 have indicated elevated levels of citrate 
synthase in patients with PAD.  Hiatt and colleagues56 showed that 3 months of 
supervised treadmill training resulted in a 26% decrease in resting short chain 
acylcarnitines and significant improvements in walking abilities and functional capacity 
as indicated by increases in MWD (123%) and VO2 peak (30%) in 10 patients with 
symptomatic PAD as compared to 8 PAD patients that received standard care.  
Additionally, the 26% decrease in acylcarnitines was negatively correlated to change in 
maximal walking time (r =-0.71, p=0.05).251 A major study by the same group confirmed 
these findings in patients randomized to treadmill training as improvement in exercise 
performance was correlated with a decrease in plasma (r=-0.67) and muscle (r=-0.59) 
short chain acylcarnitine concentrations.  The lowering of acylcarnitine concentration 
likely is attributable to enhanced acetyl CoA oxidation, and an indirect marker of 
improved TCA cycle functioning.   
Investigations which pertain to the analysis of both glycolytic and oxidative 
enzymes prior to and following aerobic exercise training intervention have given support 
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to enzymatic adaptations in patients with PAD.  Hiatt et al,56 in addition to the 
measurement of acylcarnitines, found that treadmill participants significantly increased 
PFK activity by 25%, while citrate synthase and LDH activity was unaltered.  This 
glycolytic response may be suggestive of a greater dependence on glucose as a fuel 
source under conditions of ischemia.  The improvement in glycolytic response has also 
been reported in an exercise training study in patients with claudication by Holm and 
colleagues.250 In addition to the glycolytic enzyme training adaptation, the 4-month 
unspecified protocol, resulted in improvements suggestive of adaptations in oxidative 
metabolism including; an enhanced ability to oxidize fatty acids, increased succinic 
oxidase activity, and elevated production of carbon dioxide.  Each aforementioned 
variable was believed to be a primary contributor to the improved walking abilities in the 
training group compared to controls subjects.250 Lundgren and colleagues,180 in an 
elaborate study, compared effects of revascularization and exercise on outcome variables 
such as ABI, hyperemic blood flow, walking ability, and the activities of glycolytic and 
oxidative enzymes.  Participants randomized to the exercise training group (n=11) did 
increase cytochrome c oxidase activity, which was positively correlated to improved 
PFWD.  This enzymatic adaptation was not found in the surgical (n=11) and surgical plus 
exercise training groups (n=11), which prompted the investigators to suggest that both the 
ischemia and physical activity were needed for enzymatic adaptations to occur.  
Summaries of studies involving enzymatic adaptations to exercise training in patients 
with PAD are found in Table 8. 
Aerobic Exercise and Endothelial Dysfunction (PAD studies) (Summarized in Table 9) 
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A 1995 review and meta-analysis by Gardner and Poehlman of 21 exercise 
rehabilitation studies in patients with PAD suggest that improvements in walking ability 
are part of the plethora of adaptations which accompany chronic treadmill training.255   
Among the studies within the meta-analysis, nine measured maximal calf blood flow 
through a variety of techniques including venous occlusion plethysmography, Xenon-133 
clearance, and thermodilution evaluation, and reported an average increase of 19%.255   
However, early studies that were included in this meta-analysis have limitations as 
several were non-randomized, lacked controls, or contained small sample sizes.  After 
this review, several clinical trials performed after this analysis, have shown that aerobic 
exercise training results in improved endothelial function similar to those found in the 
aforementioned meta-analysis.57,256-258  
Research by Brendle and Gardner259 showed enhanced post occlusive reactive 
hyperemia, as measured by FMD and strain gauge plethysmography, in 19 patients with 
claudication following 6 months of treadmill training characterized by walking bouts of 
near maximal claudication.   Although no control groups were present in this study, 
patients increased max calf blood flow (as assessed strain gauge plethysmography) by 
35% (p=0.04) and also exhibited a 15% (non-significant, p=0.1) increase in blood flow 
after 1 minute post occlusion reactive hyperemia.259 (It should be noted that max calf 
blood flow or maximal hyperemia was measured following plantar flexion exercise with 
cuff-induced arterial occlusion).  After exercise training, patients also demonstrated a 
significant 61% increase in flow-mediated brachial diameter (p<0.005) as measured by 
FMD. However, the results of this study should be used with caution as this study was 
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not a randomized, controlled trial.  In a large clinical trial, Gardner et al258 showed 
significant increases in maximal hyperemia of 30% and MWD by 77%, where the PAD 
patients (n=31 exercise training group, n=30 standard of care group) used the same 
training protocol as prescribed earlier by Brendle and Gardner.259   Unlike previous 
findings, the improvements in endothelial function (as suggested by maximal hyperemia) 
were significantly related to improvements in maximal walking distance (r=0.38, 
p=0.47).258   
Follow-up clinical trials by the same group of researchers, resulted in similar 
findings as 17 patients with claudication that completed 6 months of treadmill training 
showed an 80% average improvement in maximal walking distance, which was sustained 
after an additional year of training (frequency 2 days per week).257   Both reactive and 
maximal hyperemic flow (measured by strain gauge plethysmography at the calf) 
significantly increased after the first 6 months of intervention compared to baseline levels 
and although did not improve during the subsequent 12 month maintenance period, were 
maintained.257   Improvements in vascular reactivity by the exercise group were also 
significant in comparison to the change experienced by that of the non-exercise control 
group (n=14).257   As with the effects of exercise training duration on the effects of 
endothelial function in patients with PAD, investigations pertaining to the outcomes of 
protocol intensities have yielded similar findings.256    
Gardner et al256 compared the patients randomized two groups, 1) low intensity 
group (n=31): exercised at 40% maximal exercise capacity; 2) high intensity group 
(n=33): exercised at 80% maximal capacity, where each group was matched for total 
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work performed as indicated by total caloric expenditure per session.  (It should also be 
noted that percentage of maximal exercise capacity refers to percentage of grade achieved 
during the baseline maximal effort treadmill test, for example, a patient that achieved a 
level of maximal claudication at 10% on the maximal effort treadmill test and was 
randomized into the low intensity group, training intensity would ensue at 4% treadmill 
grade.) After 6 months of training, both groups significantly increased both maximal and 
pain free walking distance (p˂0.05) and reactive and maximal hyperemia (as measured 
by strain gauge plethysmography at the calf).   Furthermore change in maximal walking 
distance was correlated to improvements in maximal hyperemia (r=0.25, p=0.46), while 
change in maximal hyperemia was an independent predictor of PFWD.256  
Findings by McDermott et al,57 Hiatt et al,251 and Nowak et al229 have produced 
similar findings as those from the Gardner group.256,257  Hiatt and colleagues251 showed 
that 3 months of supervised treadmill training resulted in a 38% increase in maximal 
hyperemia and 123% improvement in maximal walking time, however these changes 
proved not to be correlated.  McDermott et al,57 also found significant increases in 
hyperemic blood flow in participants randomized to treadmill training, a first to our 
knowledge that demonstrates that exercise improves brachial artery flow mediated 
dilation in patients with PAD.   For brachial artery FMD, PAD patients in the treadmill 
group had a mean improvement of 1.53% (95% CI, 0.35%-2.70%; P=0.02) compared to 
control subjects.  In addition patients with claudication increased maximal walking time 
by 3.44 minutes (95% CI, 2.05-4.84 minutes: P˂0.001) compared to patients in the 
control group.57 The former suggests that supervised treadmill exercise training promotes 
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a favorable systemic vascular effect (improved endothelial function) with the potential to 
result in a reduction in cardiovascular events in those with claudication.  Lastly, research 
from Novak and colleagues,229 showed that 12 weeks of both pain-free and moderate 
(walking bouts to moderate levels of claudication) treadmill training improved FMD 
levels, albeit non-significantly (actual results not shown).  The authors stated that the 
findings would have likely reached significant levels if the study had more participants 
(n=12).  Due to this limitation and a lack of a control group, results of this study should 
also be viewed and interpreted with caution.  A summary of the effects of exercise 
training on endothelial functioning in patients with PAD are found in Table 9. 
Aerobic exercise is a potent activator of the NO/cGMP pathway that supports the 
vasodilatory capabilities of the arteriolar system.260 The stimulus for this exercise-
induced activation of the NO/cGMP pathway is primarily due to an increase in the 
bioavailability of NO.  Exercise intermittently changes the magnitude and frequency of 
physical forces (including laminar shear stress) that upregulates several atheroprotective 
genes, including eNOS.202 Additionally, laminar shear stress can increase the formation 
of another atheroprotective antioxidant (MnSOD) within the endothelium.147  The 
increased expression of MnSOD lowers the O2- induced formation of ONOO- from NO, 
which is essential in reducing the uncoupling of eNOS, and the subsequent suppression in 
NO bioavailablity.  Furthermore, the resulting formation of H2O2 from the dismutation of 
O2- , leads to the increased expression and activity of eNOS through transcriptional and 
post-transcriptional modifications.261  
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Chronic aerobic exercise training can positively alter NO bioavailability through 
its anti-inflammatory mechanisms.  During rhythmic skeletal muscle contraction, IL-6 is 
produced by activated muscle fibers, which is believed to stimulate the appearance of 
other anti-inflammatory cytokines, such as IL-10 and IL-1ra.24,27 Aerobic exercise 
training is also known to have potent immunomodulatory effects.  In addition to the IL-6-
induced production of IL-10, T-helper cells (type 2) and T-regulatory cells, also 
contribute to the systemic elevation of IL-10 after exercise training.262 IL-10 and IL-1ra, 
inhibit the production of proinflammatory cytokines, most notably TNFα.24,262 TNFα, as 
previously discussed, reduces the bioavailability of NO through several mechanisms 
including: the direct downregulation of eNOS mRNA, suppression of DDAH, and 
production of O2- from enzymatic sources such as NADPH, XO, and iNOS.81  IL-10, in 
addition to its inhibitory effects on TNFα production, suppresses macrophage chemokine 
production and inhibits leukocyte-endothelial interactions,263 which can lower O2- 
production at the vascular endothelium. This link between anti-inflammatory cytokines 
and oxidative stress is supported by research Kodja et al260 who concludes that the down 
regulation of NADPH oxidase following aerobic exercise training is partially due to 
concurrent systemic elevation of IL-10, and is therefore a major vasoprotective effect of 
exercise training. 
Lastly, ischemia-inducing exercise training has been shown to stimulate an 
increase in heat shock proteins (HSP).49 HSP-90 may be especially important as it acts as 
a scaffolding for eNOS, thereby promoting enzymatic stability (one of the detrimental 
effects of a proinflammatory environment).  In addition to adenosine,51 HSP’s are 
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reported to be important mechanisms in IPC, and may prevent eNOS degradation in 
periods of ischemia and hypoxia.264 An increase in HSP’s therefore have the potential to 
positively influence NO bioavailability, in patients with ischemic diseases such as PAD.  
The potential mechanisms of exercise, inflammation, and endothelial dysfunction are 
shown in Figures 3 & 4 and Table 10. 
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Chapter III 
Methods & Materials 
Description of Study Design 
This dissertation is a secondary analysis of blood samples obtained from the 
parent study titled EXERT (Exercise Training to Reduce Claudication).  EXERT, is a 
NIH-funded study (NCT00895635), led by Dr. Diane Treat-Jacobson, the primary 
investigator.  The protocol for the EXERT study relevant to my dissertation topic is 
discussed below.  In addition to the general protocol, the methodology for the biomarker 
analyses on stored plasma in current and past participants are discussed below (Blood 
Biomarkers of Inflammation and Oxidative Stress).   
EXERT Protocol  
The EXERT study is a randomized, controlled trial.  Subjects were stratified by 
gender, and randomly assigned to one of 3 groups: (1) Control or Usual Care  (n=30), (2) 
Treadmill Walking (n=60), and (3) Arm Ergometry (n=60) for a 12 weeks of intervention 
with a subsequent 12 week follow-up period.  Permuted block randomization using 
blocks of 5 and 10 was used to balance treatment groups over time.  Data was collected at 
baseline, 6, 12, and 24 weeks.   For this disseration, the first 75 participants who 
completed the initial 12 weeks of the study, and had blood drawn (at baseline and 12 
weeks) were included for analysis.  The primary study endpoints are change in 
inflammation and oxidative stress as indicated by plasma cytokines (TNFα and IL-10), 
and oxidative stress (F2-isoprostanes) biomarkers.  
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Study Participants 
Criteria for Inclusion.  
To be eligible for the study, individuals had to be >18 years of age, and had 
exercise and lifestyle limiting claudication due to PAD with an ankle brachial index 
(ABI) of <0.90 and a further 10% decrement in ABI following a symptom-limited 
treadmill exercise.  To be eligible for the study, individuals had to provide written 
informed consent, be able to walk at 2.0 mph on a treadmill, and be willing to perform a 
12-week exercise program.   Individuals with either type 1 or type 2 diabetes mellitus 
were eligible for participation provided that they had fasting glucose levels within the 
acceptable range for exercise according to American College of Sports Medicine 
guidelines.265 
Criteria for Exclusion.   
Individuals were excluded if they had uncontrolled hypertension (>200 mmHg 
systolic blood pressure and/or diastolic blood pressure >100mmHg), since this generally 
is a contraindication for exercise participation. Other exclusionary criteria included 
ischemic rest leg pain and/or leg/foot ulceration, or impending gangrene.  Further 
exclusionary criteria included exercise capacity limited by health problems other than 
claudication (e.g., angina pectoris, severe arthritis, extreme dyspnea on exertion, or 
unstable coronary heart disease); lower extremity or coronary revascularization within the 
past 3 months prior to enrollment;  and currently taking medications to reduce 
claudication (i.e. cilostazol and pentoxyfylline) unless these medications were initiated at 
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least three months before study enrollment.  Additionally, participants were excluded 
from analysis if these pharmacological agents were initiated or discontinued during the 
study duration.  The use of prescribed cardiac and or blood pressure control medications, 
were also not exclusionary.  The rationale for this was to achieve a balance between 
being broadly inclusive while ensuring clinical stability of the study participants at the 
time of study enrollment.  Any changes in prescription medications that occurred during 
the study were documented in the participant’s record.  Lastly, all dietary supplements 
with known anti-inflammatory and antioxidant effects such as 
multivitamins/antioxidants, omega 3 fatty acids, etc. did not result in exclusion from 
EXERT and from this ancillary study. 
Study Methodology. 
Graded Cardiopulmonary Treadmill Tests for determination of MWD.   
A graded exercise test (GXT) was performed, at each of the study periods, in the 
post-absorptive state with no smoking or caffeinated beverages permitted in the previous 
3 hours.  Participants were instructed to take their usual medications with the exception 
of insulin or oral hypoglycemic agents for subjects with diabetes, which were withheld 
until after the GXT. All GXTs were supervised by a physician to ensure patient safety. 
Heart rate and rhythm was monitored by continuous 12 lead ECG during the GXT.  
Blood pressure was assessed before the GXT, at three minute intervals during the test, 
and post-exercise at 1, 3, and 6 minutes.  The GXT was initiated with participants 
walking on the treadmill at a speed of 2 mph and at a 0% grade (flat).  The grade of the 
treadmill was progressively increased 3.5% every 3 minutes until a grade of 10.5% was 
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achieved, at which time the speed subsequently was increased by 0.5 mph every 3 
minutes, while the grade was maintained at 10.5%.  This is approximately equal to an 
increase of one MET per stage of the test.  Participants were only permitted to touch or 
hold the handrail lightly in order to maintain balance. 
During the treadmill exercise test, participants were asked to rate the severity of 
their claudication pain every 30 seconds, using the following claudication pain scale:  
0=no pain, 1=initial onset of mild claudication pain, 2 and 3=moderate pain, 
4=submaximal, and 5=maximal claudication pain, the point at which the participant could 
no longer tolerate the pain. The distance walked prior to initial onset of pain was defined 
as pain free walking distance (PFWD) and the distance at which the participant must stop 
due to claudication pain was defined as the maximal walking distance (MWD).      
EXERT Study Intervention Protocol 
Exercise groups (arm ergometry or treadmill walking).   
EXERT participants randomized to an exercise group could select 1 of 6 exercise 
rehabilitation sites to complete their exercise training.  Exercise sessions were held 3 
times/week for 12 weeks for a total of 36 sessions.  Sessions were 70 minutes in length, 
including 5 minutes of warm-up, 60 minutes of exercise and 5 minutes of cool down.  
Exercise intensity was prescribed to maintain a rating of perceived exertion (RPE) of 13-
15 using the Borg RPE scale 6-20.   Exercise intensity was further modified to 65-80% of 
achieved VO2 reserve as calculated from the achieved VO2 peak during the baseline GXT 
(VO2 reserve = VO2 peak –VO2 rest ), VO2 reserve is approximately equal to heart rate 
reserve. Intensity was initiated at 65% and progressed by 5% increments as tolerated until 
it reached 80%.  Exercise intensity was further adjusted to allow the participant's heart 
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rate not to exceed 85% of peak heart rate achieved during the baseline GXT.  These 
modifications of the exercise training programs were done to provide both groups with 
similar intensity and volume of exercise training.  An exercise therapist provided 
individualized attention and directed the progression of exercise training in accordance 
with the protocol.  For each individual, the total amount of work performed was 
calculated and recorded for each session and for the total exercise program.  Heart rate, 
RPE, and claudication pain were recorded by the exercise staff every 3-5 minutes to 
assess the physiological response to exercise and to determine how the participants 
response changed with increased workload.  Blood pressure was assessed at rest, during, 
and after each exercise session.  Documentation of the speed, grade and/or workload in 
watts, in addition to time exercising and time resting, allowed for quantification of the 
work performed at each session.  Exercise adherence was monitored continuously, and 
participants were encouraged to make up any missed sessions.  Participants were also 
questioned regarding any health-related events that may have occurred since the previous 
visit.  Participants were not permitted to train more than 4 sessions per week.   
Treadmill Walking.   
The treadmill walking group participants began exercising at the grade and speed 
that elicited onset of claudication during their initial baseline treadmill test. They walked 
until the claudication pain became moderate to moderately-severe (3 to 4 out of 5 on the 
claudication scale), and then rested, steped off the treadmill and sat in an adjacent chair 
until the pain subsided.  Exercise/rest periods were repeated throughout the exercise 
training session (60 minutes). The amount of work performed was estimated from the 
speed and grade of the treadmill and was recorded in metabolic equivalents (MET x 
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minutes) using a standard formula.   After the participant was able to walk 8 minutes at 
the initial workload without stopping, the grade was increased by 1.0% grade at the 
beginning of the next session.  Increases in grade continued until the treadmill was at a 
10% grade, at which time the speed was increased by 0.1 increments beginning at the 
start of the next session.  After the participant was able to walk at a 10% grade and 3 mph 
for 8 minutes without reaching a 3 to 4 on the claudication scale, the grade was increased 
at 1% increments until a 15% grade was reached. Most participants were not expected to 
be able to reach this intensity during the 12 weeks of exercise training.  If a participant 
was able to walk for 8 minutes at 15% grade and 3 mph without reaching 3 to 4 on the 
claudication scale, the speed was again increased by increments of 0.1 mph.  Limiting the 
initial grade to no more than 10% was intended to reduce the risk of back, knee, and hip 
orthopedic injuries, and to reduce the tendency of participants from holding too tightly to 
the handlebars, thereby decreasing the intensity of the exercise.  Initial pilot experience 
indicated that exercise training above 10% grade may cause some participants to stop 
before moderate claudication pain was achieved.  
Arm Ergometry Training.    
Each participant began exercising at one work level (in watts) below the maximal 
watt-level achieved during the arm ergometry test.  Participants worked against this load 
intermittently in cycles of 2 minutes of exercise, followed by 2 minutes of rest for a total 
of 60 minutes (this equates to 30 minutes of exercise and 30 minutes of rest). After 3 
weeks of training, the intensity was increased to the work level (in watts) achieved during 
the arm ergometer test.  Exercise increments were increased by 1 minute every 2-3 weeks 
during the training period and the rest periods decreased to 1 minute for a maximal 
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volume of intervals of 5 minutes of exercise and 1 minute of rest per cycle for a total of 
60 minutes.   
Control Group Receiving Usual Care.   
Individuals who are randomized to the control group were instructed to continue 
their “usual care" for their claudication, as recommended by their primary care provider. 
They also were provided with specific, standardized, written exercise instructions 
(specific for patients with PAD) by the American Heart Association.22 Further, they were 
seen weekly by study personel for blood pressure and heart rate assessment.  The weekly 
visits and specific walking exercise instructions provided attention to the control group 
with the goal of increasing their retention.    
 
Blood Biomarkers of Inflammation and Oxidative Stress.   
Measures of oxidative stress (F2 isoprostanes) and inflammation (TNFα and IL-
10), were obtained according to standard laboratory protocols.  Blood samples were 
collected following an overnight fast via venipuncture in the morning between 8-11AM 
to control for diurnal variability in biomarker levels. A small gauge needle was used to 
withdraw a small sample (approximately 3 teaspoons) of blood from a vein in the 
participant’s arm.  Blood was collected using EDTA as an anticoagulant for tubes to be 
analyzed for cytokines and isoprostanes respectively.  Blood samples were immediately 
centrifuged for 10 minutes at 2700RPM’s, and plasma aliquots in duplicate were 
collected and stored at -80°C.  Analyses were performed in the University of Minnesota 
Medical Center’s cytokine laboratory of Dr. Angela Panoskaltsis-Mortari (CLIA license 
number: 24D0931212).  Plasma samples were assayed by an experienced lab techinician 
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blinded to study group assignment to reduce the potential for bias, using the 
commercially available Fluorokine® MAP Multiplex Human High Sensitivity Cytokine 
Panel (3 plex from R&D systems, Minneapolis, MN) for inflammatory cytokines and F2 
isoprostane EIA kit (from Cayman Chemical, Ann Arbor, MI) for F2 isoprostanes 
according to manufacturers’ instruction. Measurement of plasma biomarkers of 
inflammation and oxidative stress were made at rest at baseline and after completion of 
the 12-week training program.  The following is a brief description of the sensitivity, 
variability, and cross reactivity for each of the individual cytokines for the multiplex 
assay, and for the single analyte for F2 isoprostanes. 
 
1. TNFα: Sensitivity (0.54 pg/mL); Range (0.82-3350 pg/mL for serum, 
heparin plasma, citrate plasma, EDTA plasma); Cross reactivity (< 0.5% 
cross-reactivity observed with available related molecules. < 50% cross-
species reactivity observed with species tested). 
 
2. IL-1ß:  Sensitivity (0.18 pg/mL); Range (0.36 - 1500 pg/mL for serum, 
heparin plasma, citrate plasma, EDTA plasma); Cross reactivity (< 0.5% 
cross-reactivity observed with available related molecules. < 50% cross-
species reactivity observed with species tested). 
 
3. IL-10:  Sensitivity (0.24 pg/mL); Range (0.51 - 2100 pg/mL for serum, 
heparin plasma, citrate plasma, EDTA plasma); Cross reactivity (< 0.5% 
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cross-reactivity observed with available related molecules. < 50% cross-
species reactivity observed with species tested). 
 
4. F2 Isoprostanes:  Sensitivity (1.0 pg/mL); Range (2.3 - 5000 pg/mL for 
serum, heparin plasma, citrate plasma, EDTA plasma); Cross reactivity 
(< 0.5% cross-reactivity observed with available related molecules. < 50% 
cross-species reactivity observed with species tested) 
 
F2 isoprostanes. 
F2 Isoprostanes are the isomers of cyclooxygenase (COX)-derived prostaglandins 
formed in vivo during the free radical-induced peroxidation of arachadonic acid,266,267  a 
major component of cell membranes (a commonly sited location of oxidative induced 
cellular damage).268,269   F2IsoP’s are valid and reliable markers of lipid peroxidation and 
afford the most accurate biomarker of oxidative stress,268,270  particularly in the presence of 
atherosclerotic diseases267,271  (including PAD272) thus, they are the most studied class of 
isoprostanes.  Specifically, isoprostanes are generally considered the “gold standard” for 
the assessment of oxidative stress in atherosclerotic cardiovascular disease 
pathophysiology267,271  and this is because of the following:270   1) the in-vivo formation of 
isoprostanes increase as a function of oxidative stress; 2) they can be measured accurately 
down to picomolar concentrations with analytical techniques including ELISA;  3) their 
measured values do not exhibit diurnal variation and likewise are not effected by the lipid 
content of the diet; 4) they are specific markers of lipid peroxidation; and 5) they are 
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present in detectable amounts in biological fluids, thus allowing a reference value.  
Further, plasma F2 isoprostanes have been measured successfully following periods of 
exercise training,273  an essential part of this protocol. 
Cytokine panel. 
The Fluorokine® MAP Multiplex Human High Sensitivity Cytokine Panel is 
compatible with the following analyte-specific bead sets:  TNFα, IL-1ß, and IL-10.  
TNFα is a proinflammatory cytokine produced and released from several cell types 
including; endothelial cells, macrophages, neutrophils, smooth muscle cells, fibroblasts, 
T-lymphocytes and mast cells in response to inflammatory stimuli from bacterial or 
paracitic infections, or following acute and chronic vascular injuries such as in 
atherosclerosis and during ischemia/reperfusion.274,275    The circulating TNFα 
concentrations are easily detectible in plasma or serum in disease states including 
PAD,78,276 while the increase in levels associated with healthy aging is far from what is 
seen with ischemic states.277    
Anti-inflammatory cytokines are a relatively new area of study in the link of 
inflammation, atherosclerosis, and exercise training.  The most commonly investigated 
anti-inflammatory cytokine (IL-10) is produced and released from monocytes, Th2 and 
T-regulatory T-lymphocytes, and is stimulated by the myokine IL-6 following acute 
bouts of exercise.  IL-10, also referred to as human cytokine synthesis inhibitory factor, is 
most commonly known for its inhibitory effects on proinflammatory cytokines including 
TNFα.27,30   Significant increases in IL-10 have been previously demonstrated following 
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the participation in exercise training in patients with chronic inflammatory conditions,278 
but has yet to be investigated in cohorts with PAD. 
 
 
Statistical Analysis.   
SPSS version 20.1 statistical software was used for all discussed analyses.  
Descriptive statistics were used to identify normal distribution of data.  If data was not 
normally distributed, an appropriate log transformation was incorporated into the 
statistical model in order to normalize the distribution.  This log transformation was done 
on baseline and 12 week plasma levels of IL-10 and F2Isoprostanes, and the subsequent 
data is expressed on both scales.  Group differences in baseline demographics and 
potential confounders were assessed by 1 Way ANOVA to determine if means were 
equivalent between the 3 training groups.   
Statistical Analysis for Specific Aim #1.   
Dependent variables were first tested for normal distribution using Shapiro-Wilk 
test of normality. As systemic biomarkers IL-10 and isoprostanes were positively 
skewed, they were normalised by logarithmic transformation before further analysis. 
These data are expressed as geometric mean values, with 95% confidence intervals in 
parentheses. Normally distributed data (including TNF) are reported as means and 
standard deviations.   Changes among groups in the primary endpoints (markers of 
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inflammation and oxidative stress) at baseline and 12 weeks were assessed using analysis 
of covariance (ANCOVA), with baseline measures being used as the covariate to 
improve the sensitivity of the analysis.  ANCOVA evaluates whether population means 
of a dependent variable (inflammatory biomarkers) are equal across levels of a 
categorical independent variable (exercise training intervention), while statistically 
controlling for the effects of other continuous variables (covariates) that are not of 
primary interest, but may affect outcome.  Additionally, adjustments for other 
confounding variables such as age, gender, BMI, smoking status, comorbidities, 
medications, and supplements that may alter the antioxidant status of the body were made 
for those measures that were not equivalent among the 3 treatment allocations. If the 
overall F test indicated there was a difference between groups in the ANCOVA, post hoc 
pair-wise comparisons, using the Bonferroni corrections to control for overall alpha level, 
was used to identify which groups were significantly different.  The Bonferroni 
adjustment was selected because it is generally considered the safest post hoc test for 
preventing type I error (that increases with the number of tests made), however this is at 
expense of statistical power.  
Statistical Analysis for Specific Aim #2.  
For the secondary aim, bivariate relationships among levels of circulating 
inflammatory mediators, and walking performance were assessed using correlation.  
Based on the distribution of variables, a Pearson’s correlation coefficient was used. 
Control of Confounders.   
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In order to control for the influence of medications that may affect the primary 
outcome (walking distances), the following precautions were made:  cilostazol and 
pentoxyfylline if taken, must have been initiated 3 months prior to study enrollment and 
all medication and supplement changes were documented as they occured during the 
study.  All participants randomized into the study were at a minimum 3 months removed 
from any vascularization procedure.  Although isoprostanes have been typically analyzed 
in urine samples, we did not have access to urine, however, analysis of isoprostanes in 
plasma is a reliable and valid marker for the determination of oxidative stress.   
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Chapter IV 
Results 
Demographic, medical, physiological, and physical variables at baseline 
 Seventy-five PAD patients with lifestyle-limiting claudication were assessed 
in this secondary analysis of the subjects in the parent study (EXERT).  In Table 11 are 
the demographic and medical data of this patient subgroup, and baseline physiological 
and physical variables are shown in Table 12.   A vast majority of this cohort presented 
with major risk factors for CVD, including past or present smoking, dyslipidemia and 
hypertension (93.3%, 80%, and 82.7% respectively), while diabetes mellitus was present 
in a smaller percentage of this cohort (25.33%).  Medications used to treat these and other 
CVD risk factors (also presented in Table 11) and smoking status were unaltered during 
the first 12 weeks of the exercise training phase of the EXERT study.  A majority of the 
patients within this cohort are classified as overweight (mean BMI = 28.7) and by their 
baseline ABI as having mild PAD (mean ABI = 0.75) with of these variables being 
similar across intervention groups, thus demonstrating successful randomization.  
Additionally 42% of this patient cohort had documented evidence of concurrent 
atherosclerotic coronary artery disease, while 50% of the cohort had undergone previous 
revascularization procedures.   
 Baseline plasma levels of IL-10 and F2 isoprostanes, but not TNFα, showed 
large degrees of variability, and as a result all subsequent results of these inflammatory 
and oxidative stress biomarker data are presented as is and also by their geometric means 
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(Table 13a-c and Figure 6b-c).  Lastly, there were no significant differences among 
groups in regards to any baseline demographic, medical, physiological, and physical 
variables.   
Intention to Treat Analyses for the Effect of Exercise Training on Inflammatory and 
Oxidative Stress Biomarkers (Tables 13a-d and Figures 6a-f) 
 Following 12 weeks of exercise training therapy or a control group receiving 
usual care, patients randomized to the treadmill training group significantly increased 
plasma IL-10 levels (unadjusted) as compared to the control group (assessed via 
ANOVA).  However, this finding lost significance using ANCOVA analysis after 
adjusting for relevant covariates such as baseline IL-10 levels and diabetes status. After 
12 weeks of intervention, patients in the control group demonstrated a significantly lower 
TNFα compared to the UBE group as demonstrated by ANOVA and pairwise 
compairisons (p=0.04).  This difference remained significant after adjusting for 
significant covariates such as baseline TNFα levels and allopurinol (p=0.022).  Lastly 
exercise training had no significant effect on circulating F2 isoprostanes, before and after 
relevant adjustments such as baseline F2Isoprostane levels and body weight.  The 
magnitude of the change in circulating IL-10 (adjusted for baseline IL-10 and diabetes) 
relative to the control group was 0.04 for the treadmill group and -0.01 for the UBE 
group.  Although circulating TNFα levels (after adjusting for baseline TNFα and 
therapeutic use of allopurinol) was increased in all 3 groups after 12 weeks of treatment, 
patients in the treadmill group showed the lowest rise (0.05 pg/ml) compared to 0.19 
pg/ml and 0.25 pg/ml increases by the control and UBE groups respectively.   Analysis 
78!
after removing 2 patients within the treadmill and UBE groups from the statistical models 
(due to influenza and exacerbation of chronic inflammatory disorders), resulted in no 
additional change in any biomarkers was observed across the 3 groups.   
Exercise Compliance Effects of Inflammation and Oxidative Stress 
 Table 14 and Figures 8a-c depict the effect of exercise compliance on 
inflammation and oxidative stress biomarkers.  When controlling for exercise 
compliance, patients who adhered to exercise (n=56) (defined as participating in aerobic 
exercise at least 3 days per week, 30 minutes per session, with 70% adherence) did not 
significantly increase TNFα or F2 isoprostanes, as compared to those who did not meet 
criteria for exercise training adherence. 
Correlations Between Inflammation and Oxidative Stress with Walking 
Performance, Physical, and Physiological Variables 
 Table 15 summarizes the Pearson’s correlations among baseline plasma 
levels of TNFα, IL-10 and F2 isoprostanes and baseline walking performance variables.  
None of these 3 biomarkers were significantly associated with baseline PFWD and 
MWD.  Additionally baseline plasma levels of TNFα, IL-10, or F2 isoprostanes were not 
significantly associated with age, smoking status or ABI (Table 17).  However, F2 
isoprostanes were significantly and positively correlated with baseline body weight 
(r=0.311, p=0.007).  TNFα also was positively associated with BMI (r=0.228, p=0.05) 
(Table 17 and Figure 9).   
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Effects of Exercise Dose on Inflammation, Oxidative Stress and Weight Change 
 We examined the effects of exercise training “dose” (total minutes exercised 
during the 12 weeks of exercise training intervention) within the treadmill and UBE 
training groups.  The mean TNFα change adjusted for baseline TNFα and allopurinol did 
not significantly differ from the 4th quartile of exercise dose (most exercise minutes 
performed) to the 1st, 2nd, or 3rd quartiles.  Additionally, a lack of significant statistical 
findings in regards to exercise dose/response was also found for change in plasma levels 
of IL-10 and F2 isoprostanes. Pearson’s correlations between change in plasma levels of 
TNFα, IL-10, and F2 isoprostanes and exercise dose (across the 4 quartiles) also failed to 
yield any significant correlations (Table 19). 
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Chapter V 
Discussion 
 Walking therapy is routinely prescribed as the initial therapy for the 
treatment of symptomatic PAD,22 however in the last decade, an alternative, pain-free, 
mode of aerobic UBE training has shown promising results in regards to improving 
walking ability in patients with PAD.58-60 The purpose of this study was to determine 
whether UBE or treadmill training (to moderate levels of claudication) influenced the 
levels of plasma markers of inflammation and oxidative stress that are associated with the 
pathophysiology of the atherosclerotic process.   In particular, we believe this is the first 
study to investigate this concept using a perceived non-ischemia producing mode of 
exercise training, i.e. UBE, in direct comparison ischemia inducing treadmill walking.  In 
PAD patients with claudication, the findings in this study suggest that treadmill training 
does not significantly increase inflammatory or oxidative stress biomarkers (TNFα and F2 
isoprostanes), which is in agreement with previous findings.227,228  In the past, it was 
postulated that although treadmill training can improve walking capacity in patients with 
symptomatic PAD, walking exercise has the potential to cause recurrent I/RI, resulting in 
chronic skeletal muscle and endothelial damage due to the deleterious effects of 
inflammation and oxidative stress.48 If this was indeed the case in our patient cohort we 
would have expected to have seen a significant rise in inflammatory and oxidative stress 
biomarkers such as TNFα and F2 isoprostanes, which was not the case in the patients who 
completed 12 weeks of treadmill exercise training.  However, neither mode of exercise 
training appeared to reduce circulating plasma levels of TNFα or F2 isoprostanes in 
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patients with symptomatic PAD.  This finding is in contrast to the commonly purported 
anti-inflammatory and anti-oxidant effects of exercise training.24,27,279-283  After adjusting 
for exercise compliance, it was found that those who exercised 3 days/week (30 minutes 
per session) throughout the study, did not significantly increase inflammation to a greater 
extent than those who did not exercise (Table 14, Figures 8a-c).   This is not the first 
study that has demonstrated a significant increase in plasma TNFα levels following 
aerobic exercise training (as found also in our UBE group).  Castellano et al284 showed 
that patients with multiple sclerosis (n=11) significantly increased TNFα following cycle 
ergometry training compared to healthy, age, and gender matched controls (n=11).  The 
exercise prescription used in this study was very similar to that used in EXERT in terms 
of intensity (60% of VO2 peak) and frequency (3 days), however the study duration (8 
weeks) and total volume of exercise (720 minutes) were lower in that study.  The 
significance of inflammatory response due to exercise training in patients with multiple 
sclerosis was unknown.  The authors reported that the perceived disability decrease and 
expected improvement in VO2 peak following exercise training suggested that changes in 
proinflammatory cytokines may not be linked to negative short-term disease outcomes. 
However, the possibility that elevated TNFα could have deleterious effects on multiple 
sclerosis over time could not be excluded.  Although the biomarkers reported in this 
study have not been used previously to evaluate the anti-inflammatory and antioxidant 
effects of exercise training in patients with PAD, other blood biomarkers including CRP, 
CAMS, HSP’s, Selectins, CD11b, CD66b, neutrophil elastase, total antioxidant capacity, 
malondaldehyde have been utilized, with varying results.52,61,227-229,285  
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 Currently, to our knowledge, six major studies have investigated the 
postulated anti-inflammatory effects of aerobic exercise training in patients with 
symptomatic PAD.  However, direct comparisons among studies are difficult because of 
different modes of exercise training variables and systemic inflammatory biomarkers 
used in these studies.  Tisi et al285 observed a significant decrease in CRP from 5.3 mg/l 
to 4.4 mg/l following 3 months of a home-based exercise program performed every day 
to the limit of claudication with a subsequent rise to 6.6 mg/l after additional 3 months of 
such training.  Saxton et al,52 in a randomized controlled trial also reported only a trend, 
without statistical significance, in lowering hs-CRP level after 24 weeks of UBE and 
lower body ergometry (LBE) exercise training.   However, in this study, exercise training 
had no effect on other inflammatory markers, including levels of VCAM-1 and ICAM-1. 
Likewise, Nawaz et al61 reported no change in E-Selectin following both UBE and LBE 
exercise training.  Both Saetre et al227 and Mika et al228 investigated the effects of 
treadmill training exercise (without control groups) on inflammatory biomarkers and had 
disparate results.  Mika et al228 showed CRP did not change in the exercise group 
randomized to a group performing moderate claudication inducing treadmill training, 
however in the treadmill group performing pain-free walking exercise showed a non-
significant increase (0.17 mg/l) in CRP after 12-weeks of training.  Lastly, Nowak229 
reported that after 12 weeks of treadmill training, patients with PAD experienced a lower 
level of IL-6 (p=0.03), but a higher level of MCP-1 (p=0.04) in the blood as compared to 
baseline levels.  Furthermore, exercise training resulted in non-significant increases in 
plasma levels of TNFα, IL-1, VCAM-1, ICAM-1, MMP-9, and non-significant decreases 
in E-Selectin, IL-10, and IL-8.   For a thorough review of the design and results of these 
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six studies that investigated the effects of exercise training on inflammation in patients 
with PAD, the reader is referred to Table 7. 
 Exercise training has been reported in several excellent reviews as having 
anti-inflammatory effects.27,279,282,286  However after a thorough review of the data from 
our study as well as other relevant exercise training studies in PAD populations 
(discussed above), there is little research to support the general consensus view that 
exercise training is anti-inflammatory in patients with symptomatic PAD.   The 
biomarker panel used in the present study (TNFα, IL-10, F2 isoprostanes), were chosen 
for the following reasons; 1) TNFα and IL-10 are strictly proinflammatory and anti-
inflammatory cytokines, respectively,81,287  2) similar to this cohort, TNFα and F2 
isoprostanes are elevated in patients with symptomatic PAD,78 3) this biomarker panel 
was used successfully to determine the anti-inflammatory effects of aerobic exercise 
training in patients with chronic heart failure,281 and 4)  F2 isoprostanes are considered 
the “gold standard” for measuring systemic oxidative stress in plasma.270 Thus, the results 
of this study suggesting that both UBE and treadmill training increase inflammation in 
patients with symptomatic PAD is surprising, due to the commonly reported anti-
inflammatory effect of exercise as discussed above.  Perhaps, if we had chosen to 
measure other indices of inflammation, we would not come to the same conclusion.   
 The anti-inflammatory effect of exercise training has generally been ascribed 
to two possible mechanisms:  increased production and release of anti-inflammatory 
cytokines from contracting skeletal muscle;24,27,281 and 2) reduced expression of toll-like 
receptors on monocytes and macrophages.279,282  However, the proposed anti-
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inflammatory effects of exercise have been postulated to be due not only from these two 
mechanisms but also from other effects of exercise. These include the inhibition of 
monocyte/macrophage infiltration into adipose tissue,288 phenotypic switching of 
macrophages within adipose tissue,288 a reduction in proinflammatory monocytes,286 an 
increase in T-regulatory and Th2 lymphocytes,289 and other factors.   
 Patients in our cohort showed an elevation of the anti-inflammatory IL-10 
following 12 weeks of treadmill training, however, this change was not significantly 
different compared to the UBE and control group.  (FIGURE 6b and 6c, and 7b)  The 
increases in plasma IL-10 are postulated to be caused by a preceding increase in the 
myokine IL-6,24 particularly following exercise training, and also from an increase in 
both Th2 cells and regulatory T-cells.290 However, it must be noted that the increase in 
IL-10 attributed to a concurrent rise in regulatory T-cells and Th2 cells are less 
established in clinical trials compared to the stimulatory effects of IL-6.  Irrespective of 
the stimuli for the training-induced increase in IL-10 within our patient cohort, the 
principal role of IL-10 appears to be containment and suppression of inflammatory 
responses so as to downregulate adaptive immune effector responses.287 IL-10 induces 
the downregulation of major histocompatibility complex antigens, CAMS, and 
compromises the capacity of effector T-cells to maintain the inflammatory response.   
Moreover, this cytokine has been postulated as the main molecule responsible for the 
“orchestra” of inflammatory reactions, especially the inhibition of the changes mediated 
by TNFα.287 
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 This is in direct contrast to our findings in that although treadmill training 
resulted in non-significant increases in plasma IL-10, TNFα also increased non-
significantly.  In exercise training studies in chronic heart failure,37,291  plasma TNFα 
levels are consistently decreased and are attributed to a concurrent rise in IL-10.281  The 
failure to find similar results may be due to the training protocol used.  The treadmill 
exercise prescription involved patients walking to a 3 or 4/5 on the EXERT leg pain 
scale, where the patients would sit down and rest until the claudication subsided, and 
would start their next walking bout.  Therefore participants in the treadmill training group 
were performing interval training, with varying degrees of continuous duration of 
exercise.  Similarly, patients in the UBE group performed progressive interval exercise 
training at work/rest ratios of 2:2, 3:2, 3:1, 4:1, and 5:1.  A limitation of the hypothesis 
that exercise-induced elevation of the myokine IL-6 and associated increase in IL-10 are 
responsible for the anti-inflammatory effect of regular exercise is that substantial 
increases in circulating IL-6 do not occur with short durations of low/moderate intensity 
exercise.292  It is possible that the interval nature of the exercise programs in our study 
was not of sufficient continous duration to elicit a strong enough stimulus to significantly 
increase IL-10 to an extent that may be required to alleviate the proinflammatory 
environment, as shown an increase in TNFα.  However, it is also important to note that 
we failed to find a dose-response relationship between minutes of exercise accumulated 
and change in plasma inflammatory and oxidative stress biomarkers (Table 19). 
 Another major source of inflammation in patients with vascular disease is 
postulated to be excess adipose tissue.24,62 The production of pro-inflammatory cytokines 
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is increased with adipose tissue expansion, where as the amounts of anti-inflammatory 
cytokines produced are reduced.293  Although, no direct measurements of truncal obesity 
such as by DEXA, or surrogate markers, such as waist circumference and waist to hip 
ratio were obtained at any point within this study, height and body weight were assessed 
and thereby BMI was calculated.   Hence, we observed a significant positive correlation 
between baseline BMI and TNFα (r=0.228; p=0.05), a finding also noted in other 
cohorts.294 After 12 weeks of intervention, patients in the UBE group showed an average 
weight gain of 3kg, while patients in the treadmill and control groups lost 0.7kg and 
1.7kg of weight respectively (TABLE 20).  However this weight change across groups 
did not reach statistical significance (p=0.678).  It is unknown how this quantity of 
weight gain in the UBE group may have influenced adiposity and inflammation, although 
weight change was not significantly correlated with change in assessed inflammatory 
biomarkers (Table 17).   Therefore it is cannot be shown in this study that the increase in 
plasma TNFα found in those in the exercise training groups was related to increases in 
adiposity, since we did not measure body fat or waist/hip ratio.  We can only speculate 
the possibility that these body composition variables increased in the UBE group, and the 
influences they may have had on the plasma biomarkers of inflammation assessed.  
However, several studies have noted a substantial weight loss may be required to 
significantly reduce plasma levels of TNFα and CRP.295,296 The study protocol of the 
EXERT study was designed to improve walking capacity in patients with PAD and not 
targeted at weight loss, so if indeed weight loss is the most important factor in the 
potential anti-inflammatory effect of exercise, we would not necessarily expect 
inflammation to decrease in our patient cohort after 12 weeks of intervention.   
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 Inflammation, and its associated cytokines or adipokines, derived from 
adipose tissue is complex and involves the infiltration of macrophages and T-cells.297 It is 
thought that the size of the adipocyte triggers the macrophage infiltration and the 
magnitude of the inflammation.298 For instance, monocytes can be differentiated into 
various macrophage subtypes upon contact with specific stimuli, such as Th1 cytokines 
(IFN and IL-1B) or Th2 cytokines (IL-10 and IL-4).    Th1 cytokines induce 
differentiation into M1 macrophage, which produces proinflammatory cytokines (TNFα, 
IL-1B, and IL-6), and are believed to be a major contributor to systemic inflammation in 
overweight and obese individuals.299,300 Aerobic exercise training is a potent stimuli for 
decreasing the size of the adipocyte as well as inducing a phenotypic switch of the 
macrophage in adipose tissue from M1 to M2.301 A recent study showed that low 
intensity exercise, consisting of walking 10,000 steps three times/week, upregulated 
markers of M2 macrophages and down regulated M1 markers.301 Although markers of 
M1 and M2 macrophages and anthropometric measurements (body fat and waist/hip 
ratio) were not measured, the increase in TNFα paired with the concurrent maintainence 
of weight and BMI suggest exercise training likely did not positively modulate the 
inflammatory environment of the adipose tissue. 
 As with systemic biomarkers of inflammation, exercise training did not 
significantly decrease plasma levels of F2 isoprostanes, which is direct contrast to 
research from several randomized trials.242,243,245  It is interesting to note that in one 
randomized trial, exercise training failed to significantly reduce F2 isoprostanes in 
patients with dyslipidemic, non-insulin dependent diabetes mellitus, another chronic 
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inflammatory disease.244 We believe that this is the first study investigating the effects of 
exercise training on systemic biomarkers of oxidative stress using F2 isoprostanes in 
patients with symptomatic PAD, therefore direct comparisons to this population are not 
possible.  Currently it is believed that the gains in aerobic fitness that are associated with 
aerobic exercise training, improve oxidative stress levels, likely because of exercise-
induced adaptations of the antioxidant defense system.238 However, we were unable to 
investigate this hypothesis, as we could not compare the change in VO2 peak after 12 
weeks of intervention to change in systemic F2 isoprostanes levels. 
 In contrast to other studies, in this study, baseline levels of inflammation 
were not correlated with physical performance variables.  Saxton et al52 reported that 
sVCAM-1 levels at baseline were moderately and negatively associated with the change 
in training limb-specific peak oxygen consumption in these patients with symptomatic 
PAD.  We did not find any such physical performance correlations as baseline TNFα, IL-
10, and F2 isoprostanes were not correlated to PFWD or MWD (Table 15).  Saxton et al52 
also reported that exercising patients in the highest quartile for circulating sVCAM-1 at 
baseline exhibited a significantly poorer improvement with training in limb-specific peak 
oxygen consumption as compared to patients in the lowest sVCAM-1 quartile.  As 
previously mentioned, we failed to find any significant correlation among baseline TNFα, 
IL-10, F2 isoprostanes with PFWD or MWD, and is in accordance to research findings by 
Nylaendar et al,302 who failed to show a significant correlation between plasma TNFα 
levels and MWD (r=-0.083).   
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 Likewise, baseline plasma inflammatory biomarkers in this patient cohort 
were not associated with disease severity, as assessed by baseline ABI (Table 17).  This 
also is in direct contrast with findings by Silvestro et al79 who found that 38 PAD 
patients, that the ABI correlated negatively with plasma levels of CRP (p < 0.05), 
sICAM-1 (p < 0.05) and sVCAM-1 (p < 0.05). Thus, in PAD, inflammatory status, 
indicated by CRP, ICAM-1, and VCAM-1 is associated with the severity of the 
circulatory impairment, but not levels of TNFα (r=-0.05; p=0.658), IL-10 (r=-0.20; 
p=0.10), and F2IsoP (r=-0.085; p=0.467) (as shown within our patient cohort). Likewise, 
Beckman and colleagues,303 using Pearson’s correlation coefficients found significant 
correleations between ABI and several systemic  inflammatory biomarkers including 
TNFα (r=0.36; p=0.001), CRP (r=0.32; p=0.001), IL-6 (r=0.29; p=0.001), and VCAM-1 
(r=0.22; p=0.025).  These findings by Silvestro et al79 and Beckman et al,303 suggest that 
inflammation may contribute to the severity of atherosclerotic burden, and associated 
morbidity.   However, the former is not reflected by baseline correlations within our 
patient cohort.  For a thorough review on the aforementioned studies the reader is 
referred to Table 1. 
Study Limitations  
 Although the results of this study suggest that both ischemia inducing 
treadmill training and non-ischemic UBE training both increase inflammation, it does not 
necessarily mean that exercise training accelerates atherosclerosis in patients with PAD.  
Exercise training is well-known to positively modulate other important mediators of 
atherosclerosis including endothelial function,257,258,304,305 glucose control,306,307 
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dyslipidemia,35,308 and hypertension,309,310 independent of its effect on systemic 
inflammation.  However, this study and 6 other previously reported studies52,61,227-229,285 
show that more research is required in order to truly call exercise training anti-
inflammatory in patients with symptomatic PAD, regardless of the exercise training 
mode.  Using the proinflammatory biomarker TNFα and  the anti-inflammatory 
biomarker IL-10 to assess inflammation within this patient cohort with symptomatic 
PAD, suggest that UBE and treadmill training are not anti-inflammatory.  However, if we 
had tested a wider array of plasma inflammatory biomarkers (CRP, CAMS, etc), toll-like 
receptors, leukocyte counts, local (muscle) effects in skeletal muscle, and direct analysis 
of plaque inflammation (via 18-F Fluorodeoxyglucose Positron Emission Tomography/ 
Computed Tomography) we might have reached a different conclusion.   Likewise, 
exercise training may induce local anti-inflammatory effects in skeletal muscle that may 
not be reflected by biomarkers in the systemic circulation.283 This shows that the 
utilization of a wider array of testing might have allowed for a more complete picture and 
analysis of the effects of exercise training on inflammation in patients with PAD.  
Although using TNFα and IL-10 allow for a basic understanding of the inflammatory 
environment, it only allows for the focus of one potential anti-inflammatory effect of 
exercise (albeit the most common hypothesized mechanism).  Inability to utilize other 
testing techniques for the analysis of the potential anti-inflammatory effects of exercise 
was the major limitation within this study.  Lastly, the last limitation was the use of 
multiple statistical comparisons following a significant F-test for the ANCOVA (for the 
primary aim).  It is wellknown that when multiple statistical tests are performed, some 
fraction will be false positives (i.e. an increase in type I error rate).  Although, we chose 
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to utilize the Bonferroni correction as it is effective at controlling for type I error, this 
may have been at the cost of statistical power. 
Future Directions 
To further elucidate a potential anti-inflammatory effect of exercise training in this 
population, a more complete analysis of testing techniques must be performed.  Systemic 
biomarkers of inflammation including cytokines/chemokines (TNFα, IL-1, IL-8, MCP-1, 
IL-10, IL-1ra, sTNFr, IFN), CAMS, HSP-70, and the acute phase reactant CRP, and toll-
like receptor 4 should be utilized to ensure all categories of systemic inflammation are 
analyzed.  In addition, local biomarkers from biopsied skeletal muscle (TNFmRNA, IL-
6mRNA, IL-1mRNA, SOD, GPx, and catalase), should be investigated to ensure that a 
local anti-inflammatory and antioxidant effect of exercise training did not occur (if not 
reflected by systemic circulation).  Measures of body composition, such as DEXA and 
surrogate markers such as waist circumference should also be performed to help 
determine if change in body composition is required for reductions in inflammation to 
occur.  If the atherosclerotic plaque is perceived to be the major source of inflammation, 
novel testing techniques such as 18-Fluorodeoxyglucose Positron Emission Tomography/ 
Computed Tomography may be utilized to determine the degree of glucose uptake by 
macrophages within the atherosclerotic plaque, and therefore reflects macrophage 
activation and inflammation.  A large scale, clinical trial should be performed with the 
aforementioned testing techniques to validate findings within this trial and to fully 
determine the effects of exercise training (that is designed to improve walking capacity) 
on inflammation in patients with symptomatic PAD.  
92!
CONCLUSIONS 
 UBE training, but not treadmill training appears to significantly increase 
plasma TNFα compared to a control group in patients with symptomatic PAD.  However, 
it should be noted that all groups increased TNFα after 12 weeks of intervention, 
including the control group receiving the standard of care.  There are several postulated 
mechanisms in regards to a lack of an anti-inflammatory effect of exercise training found 
in this patient cohort which include:  1) exercise does not decrease inflammation in 
patients with PAD (contrary to common belief), 2) the aerobic exercise prescription was 
not continuous and inadequate to stimulate significant IL-6 and IL-10 production to lower 
TNFα, 3) weight loss may be required for an anti-inflammatory effect (which was not 
generated by our exercise program), and 4) the exercise training may have induced a 
local anti-inflammatory effect that was not reflected in the systemic circulation.  
Inflammatory biomarkers were not correlated with PFWD and MWD as previously 
reported, nor were they correlated with disease severity (ABI) in patients with PAD.  
Much more research is required to call exercise training in patients with PAD as anti-
inflammatory.  To further elucidate a potential anti-inflammatory effect of moderate 
intensity aerobic exercise training in this population, a more complete analysis with 
testing techniques designed to assess inflammation systemically and locally (i.e. 
atherosclerotic plaque, adipose tissue, and lower extremity skeletal muscle) must be 
performed.
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Table 1:  Inflammation, Oxidative Stress, Antioxidant Activity in PAD 
STUDY Subjects 
(PAD/Controls) 
MARKERS SAMPLE; TESTING 
METHODS 
FINDINGS 
Edwards158 N=38 (19/19) 
ABI: 0.82 (Median) 
Neutrophil Count, TXA2 
vWF, GPX, and Se 
Plasma and Leukocytes; ELISA;  GPX & Se significantly ↓ in PAD vs. 
Controls 
Pipinos97 N=41 (25/16) 
ABI: 0.34 (PAD & CLI 
patients) 
Protein carbonyls 
Lipid hydroperoxides 
4-hydroxy-2-nonenal  
Muscle biopsy; ferrous 
oxidation/xylenol orange technique 
(LHP), EIA (PC), 
chemiluminescence (HNE) 
PC, LHP, and HNE sig ↑ PAD 
vs. Controls 
Khaira83 N =29 (20/9) 
ABI: 0.58  
TAC Venous blood (AO) – enzyme 
horseradish peroxidase and urine 
(ACR) after 90 min rest 
No difference in TAC between PAD and 
Controls at rest (attributed to small n) 
Pipinos97 N=41 (25/16) 
ABI: 0.34 (PAD & CLI 
patients) 
Activities of Mn & Cu-
Zn SOD 
GPX, CAT 
Muscle biopsy; Method of 
McCord and Fridovich (MnSOD 
and Total SOD), Total SOD – 
MnSOD (CuSOD), Method of 
Flohe and Gunzler (GPX),  
Mn SOD sig ↓ PAD 
CAT & GPx sig ↑ PAD 
No differences in Cu-Zn SOD 
Langois74 N=198 (85/113) 
ABI: 0.61 
L-ascorbic acid, 
Fibrinogen, CRP 
Serum; ascorbate oxidase method 
(Vitamin C), high-sensitive latex-
enhanced immunonephelometry 
(CRP) 
Vitamin C significantly ↓ and CRP 
significantly ↑ in PAD vs. control 
Turton160 N= 68 (46/22) 
ABI = 0.73 
TAC Whole blood and Serum; ELISA, 
Chemilluminescence Assay  
 
No difference in TAC b/w groups  
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STUDY Subjects 
(PAD/Controls) 
MARKERS SAMPLE; TESTING 
METHODS 
FINDINGS 
Signorelli78 
 
N=40 (20/20) 
ABI = 0.72 
TNF, IL-6, E, P, L-
Selectin, VCAM, ICAM 
Mononuclear cells and plasma; 
ELISA 
TNF and IL-6 in PAD patients 
significantly ↑ vs. controls  
Tisi285 N=82 (67/15) 
 
CRP, Fibrinogen, SAA Serum; ELISA CRP, SAA, and Fibrinogen all 
significantly ↑ in PAD vs. Controls 
Fiotti276 N=24 (8/8/8) 
PAD/Control/CLI 
ABI 
IL-1B, TNF, IL-6 TNFr 
(I & II), IL-1r, IL-6r, IL-
1ra, CRP 
Plasma; quantitative sandwich 
enzyme immunoassay technique 
TNFr (I &II), IL-1r, IL-6r, IL-1ra 
significantly ↑ in PAD vs. controls  
Brevetti311  N=48 (34/14) ICAM, VCAM Plasma; ELISA ICAM significantly ↑ in PAD vs. 
Control.  No difference for VCAM.   
Beckman303  N=110 (60/50) 
ABI=0.68 
CRP, ICAM, VCAM, 
TNF, IL-6 
Plasma; ELISA TNF, CRP, IL-6 significantly ↑ in PAD 
vs. Controls.  No differences for VCAM 
or ICAM.  All significantly correlated to 
ABI (Except ICAM) 
McDermott10 N=549 (346/203) 
ABI =0.65 
CRP, SAA, Fibrinogen Plasma; High Sensitivity 
immunotechniques 
Fibrinogen and CRP significantly ↑ in 
PAD vs. Controls 
Nylaendae302 N=127 (127/0) VCAM, ICAM, E & P-
Selectin, TNF, IL-6, IL-
10, CD-40, MCP-1 
Serum; ELISA TNF, IL-6, CD-40, MCP-1 significantly 
correlated to angiographic score 
(unadjusted).  CD-40, MCP-1 (remained 
significant after adjustment) 
McDermott312 N=956 (107/848) CRP, Fibrinogen, TNF, 
IL-1B, IL-6, IL-10 
Serum and Plasma; ELISA IL-6, CRP, Fibrinogen, IL-1ra significant 
in PAD vs. Control  
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Table 2:  Mitochondrial Dysfunction: Impaired Oxygen On-kinetics Studies in PAD 
STUDY Subjects 
(PAD/Controls) 
PROTOCOL TESTING METHODS FINDINGS 
Bauer167 N= 12 (6/6) 
ABI=0.62 
Constant Load GXT NIRS (St O2 or Hgb 
Desaturation) 
Kinetic time of StO2 desaturation was prolonged in PAD vs. 
C (21.9 vs. 4.9 sec (p≥0.01) 
Barker168 N=18(10/8) 
ABI =0.73 
GXT VO2 kinetics & Biopsy: 
PDCa) 
Impaired VO2 kinetics with onset of exercise correlated with 
walking time (r = -0.72), peak VO2 (r = -0.66), and ABI in 
PAD, but not controls. PDCa not correlated with PAD, but 
with impaired VO2 kinetics during exercise (r = -0.56). 
Bauer164  N=24(15/9) Constant Load GXT VO2 kinetics VO2 kinetics significantly slowed for PAD group vs. 
controls, no correlation with disease severity (ABI) 
Bauer167  N=12 (6/6) 
ABI= 
Arms vs. Legs VO2 kinetics, Reactive 
Hyperemia 
StO2 desaturation kinetics were slowed at the onset of 
treadmill exercise in PAD vs. Controls 
 
 
 
 
 
 
96#
Table 3: Mitochondrial Dysfunction: Impaired Oxidative Phosphorylation in PAD 
STUDY SUBJECTS 
(PAD/Controls) 
PROTOCOL TESTING METHODS FINDINGS 
Keller177  N=18(11/7) 
ABI= 
Ischemic exercise PCr, ABI, angiography PCr recovery correlated to ABI (r=0.74, P=0.019) and 
angiography (r=0.89, P=0.005) 
Williams313 N=25 (16/9) 
ABI= 0.53 
Isotonic PCr, ABI, angiography PCr recovery correlated to angiography, but not ABI 
Anderson98 N = 85 (85/0) 
ABI = 0.69 
Isotonic plantar 
flexion 
P31 MRS & MRI– calf muscle 
perfusion & PCr recovery 
No correlation between tissue perfusion and PCr recovery – 
suggests that blood flow and metabolism are uncoupled 
Isbell170  N =34 (20/14) 
ABI = 0.62 
Isotonic plantar 
flexion 
P31 MRS, PCr recovery Median recovery time of PCr was 37.4 sec in normal vs. 91.0 
seconds in PAD (significant). No correlation of PCr recovery 
to ABI (p=0.68) 
Kemp174 N= 20 (11/9) 
ABI = 0.73 
Isometric plantar 
flexion 50-75% 
MVC 
PCr recovery & NIRS Slower PCr recovery (47%) compared to controls, PAD had 
larger PCr changes during exercise (shortfall of OXPHOS) 
Pipinos173 N = 26 (12/14) 
ABI= 0.5 
90 sec submax 
Isometric plantar 
flexion 
P31 MRS 
PCr and ADP recovery times 
PCr & ADP recovery time 137 sec (PAD) and 60 sec 
(control) were significantly different 
Greiner176  N= 26 (17/9) 
ABI= 0.72 
Isotonic plantar 
flexion 30/min 
(power output 2W) 
P31 MRS 
PCr recovery 
Compared to normal controls only the symptomatic legs in 
PAD showed significant PCr recovery (time) following 
exercise at 5 W.  Time correlated to ABI in PAD group 
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Table 4:  Mitochondrial Dysfunction: Calf Muscle Enzymatic Studies in PAD 
STUDY SUBJECTS 
(PAD/Controls) 
PROTOCOL TESTING METHODS FINDINGS 
Hiatt187 N=18 (11/7) 
ABI= 0.72  
Resting & Peak 
treadmill test 
Plasma long & short-
chain acylcarnitines and 
total carnitine 
Post exercise long chain and total acylcarnitines were significantly 
↑ from resting values (+0.6 & +2.1 respectively): values dropped 
in controls 
Hiatt96 N=16 (10/6) 
ABI 
(unilateral) 
Resting & Peak 
treadmill test 
Biopsy & plasma 
carnitine and 
acylcarnitine 
At rest carnitine levels significantly lower in symptomatic legs vs. 
both legs and long chain acylcarnitines were significantly higher in 
symptomatic legs vs. controls.  LCAC were significantly elevated 
in PAD vs. controls post exercise 
Pipinos97  N = 41 (25/16) 
ABI = 0.34 
NA Biopsy & Respirometry Complexes I (0.067 vs. 0.086), III (2.33 vs. 2.72), IV (0.042 vs. 
0.062) have significant ↓ activity vs. controls (normalized to 
citrate synthase) 
Pipinos161 N = 18 (9/9) 
ABI = 
NA Biopsy & Respirometry Mitochondrial respiratory rate is deficient after addition of malate 
& glutamate (substrate) in PAD calf vs. controls 
Brass95 N= 26 (17/9) 
ABI= 0.64 
NA Biopsy & Respirometry NADH dehydrogenase (I) activity and cytochrome c 
oxidoreductase (III) were significantly ↓ in PAD vs. controls (2.45 
vs. 3.35) & (7.35 vs. 9.34) * normalized for citrate synthase 
Bhat141 N= 18 (8/10) 
ABI= 0.5 
NA DNA extraction via 
biopsy; assay: 4797-bp 
deletion freq. 
% mtDNA with 4797-bp deletion was significantly ↑ in PAD (both 
symptomatic and asymptomatic legs vs. controls (0.88  vs. 0.43 vs. 
0.05)  
Brass142 N= 9 (9/0) NA Bhat et al 141  PAD is associated with mtDNA deletions  
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Table 5:  Acute Effects of Exercise on Biomarkers of Inflammation and Oxidative Stress in PAD 
STUDY* SUBJECTS*(PAD*/*
Control)*
DESIGN*/*PROTOCOL* SAMPLE/*TESTING*
METHODS*/*MARKERS*
FINDINGS*
Signorelli78# N=40#(20/20)#
ABI#=#0.72#
Cross>Sectional;#5#
minute#marching#
Mononuclear#cells#and#
plasma;#ELISA;#TNF,#IL>6,#E,#
P,#L>Selectin,#VCAM,#ICAM#
Significant#↑#in#TNF#and#IL>6#in#PAD#vs.#Controls#
following#Acute#Exercise#
Fiotti276# N=16#(8/8)# Cross>Sectional;#30#
minute#walk#(samples#
taken#IPE#&#4hr.#post#
exercise)#
Plasma;#quantitative#
sandwich#enzyme#
immunoassay#technique;#
IL>1B,#TNF,#IL>6#TNFr#(I#&#
II),#IL>1r,#IL>6r,#IL>1ra,#CRP#
No#significant#differences#between#groups#at#IPE#or#4#
hour#plasma#biomarkers#
Edwards158# N=18#(11/7)#for#
Leukocyte#and#
Inflammation;#N=38#
(19/19)#for#ROS#
Scavengers#
Cross>Sectional;#5#
minute#treadmill#test#
Plasma#and#Leukocytes;#
ELISA;#Neutrophil#Count,#
TXA2#vWF,#GPX,#and#
Selenium#
Resting#Neutrophil#count#significantly#↑#in#PAD#vs.#
Controls#while#GPX#and#Selenium#levels#significantly#↓#
in#PAD#vs.#controls#post#exercise.#
Khaira314# N#=29#(20/9)#
ABI:#0.58#
Cross>Sectional;#
Treadmill#exercise#
Plasma;#
Chemilluminescence#
Assay;#TAC#
TAC#significantly↓#in#PAD#vs.#Controls#post#exercise#
Andreozzi315# N=18#(11/10/8)#
PAD/CLI/Control#
Cross#Sectional;#
Maximal#Treadmill#
Test#
Plasma;#ELISA;#IL>6,#IL>1B# PAD#and#CLI#patients#significantly↑#IL>1B#and#IL>6#
immediately#post#exercise#compared#to#controls##
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Table 6:  The Effects of Exercise Training on the Biomarkers of an Acute Inflammatory Response in PAD 
STUDY SUBJECTS DESIGN / 
PROTOCOL 
SAMPLE/ TESTING 
METHODS / 
MARKERS 
FINDINGS 
Turton160 N=66 (46/22) Cross Sectional + 
Intervention; 
Static RT and 
Treadmill walking (+5 
Claudication): 
Duration: 12 weeks  
Lipid Peroxidation 
(MDA), Neutrophil 
Activation (CD-18b) 
TAC, (Measured: Pre & 
30 min post-exercise) 
Baseline:  Acute exercise significantly ↑ CD-18b & 
MDA from resting levels in PAD vs. Controls 
Post Training Intervention: Non-significant rise in 
CD-18b and MDA following acute exercise in PAD 
group 
Nawaz61 N=67  (26/26/15) 
(UBE/LBE/C) 
Cross-Sectional + 
Intervention;  UBE vs. 
LBE vs. C; Duration 6 
weeks 
Plasma; EIA Neutrophil 
Activation (CD11b, 
CD66b), E-Selectin, vWF 
Baseline:  LBE significantly ↑ CD-11b & CD66b from 
resting levels in PAD vs. Controls, not evident with 
UBE exercise 
Post Training Intervention:  LBE significantly ↑ CD-
11b & CD66b from resting levels in PAD vs. Controls 
(regardless of training group), not found with acute 
UBE exercise test 
Nowak229 N=12 (12/0) Cross-Sectional + 
Intervention; 
Treadmill Training; 
Duration 12 weeks 
Plasma; Multiplex EIA 
Assay; E-Selectin, 
VCAM, ICAM, MPO, IL-
1B, IL-6, IL-10, IL-12, IL-
17, MCP-1, TNF, IFN and 
SOD-1 (Leukocyte) 
Baseline: Acute exercise significantly ↓ TNF alpha and 
significantly ↑ SOD1. No significant change in other 
biomarkers  Post Training Intervention:  Acute 
exercise significantly ↑ SOD1.  No significant change in 
other biomarkers 
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Table 7:  The Effects of Exercise Training on Resting Biomarkers of Inflammation and Oxidative Stress 
STUDY& SUBJECTS& DESIGN&/&
PROTOCOL&&
SAMPLE/&TESTING&
METHODS&/&MARKERS&
FINDINGS&
Nawaz61 N=67  (26/26/15) 
(UBE/LBE/C) 
Cross-Sectional + 
Intervention;  UBE 
vs. LBE vs. C; 
Duration 6 weeks 
Plasma; EIA; Neutrophil 
Activation (CD11b, 
CD66b), E-Selectin, vWF 
No significant change in E-Selectin, CD-11b, or CD-
66b in either training group was present  
Saxton52 N=92 (32/30/30) 
(UBE/LBE/C) 
Intervention;  UBE 
vs. LBE vs. C; 
Duration 24 weeks 
Serum, EIA; VCAM, 
ICAM, CRP, HSP-60, 
HSP-70 
Exercise had no significant effect on any biomarker.  
UBE group ↓ CRP (approached significance).  
Tisi285 N=39 (22/17) Interventional; Active 
& Passive Leg 
Exercise + Daily 
Walking vs. Controls; 
Duration; 4 weeks 
Serum; ELISA; 
Fibrinogen, CRP, SAA 
Exercise training group had significantly ↓ CRP (at 3 
month follow-up) and ↓ SAA (at 6 month follow-up vs. 
Control subjects.    
Mika228 N=60 (30/30) – 2 
Exercise groups 
Interventional; PFTT 
vs. MTT; Duration: 
12 weeks 
Serum; Method of Clauss 
& Nephelometric Method; 
Fibrinogen and CRP 
No significant changes in Fibrinogen or CRP following 
training in either group 
Nowak229 N=12 (no control) Interventional; TM 
training; Duration 12 
weeks 
Plasma; Multiplex EIA 
Assay; E-Selectin, VCAM, 
ICAM, MPO, IL-1B, IL-6, 
IL-10, MCP-1, TNF, IFN  
Exercise training significantly ↓ IL-6, but significantly 
↑ MCP-1.  No significant changes in any other 
biomarkers. 
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Table 8:  Exercise Training Effects on Enzymatic Function in PAD 
STUDY SUBJECTS DESIGN*/*
PROTOCOL* 
TESTING METHODS FINDINGS 
Hou186  N=26 (15/11) 
Trained and 
untrained PAD 
ABI=0.68 
Training: 16 
weeks walking 
or cycling (3 x 
week, 30-60 
min) 
Biopsy:  3 combinations 
of substrate added, max 
ATP production taken 
Trained PAD muscle has significantly better capabilities to oxidize 
CHO, but not esterfied FA 
Lundgren180  N=58(38/20) Surgery, 
Surgery + 
Exercise, 
Exercise only  
Biopsy: PFK, LDH, CS, 
3HCoA-DH, Cyt-c-ox 
No change in 3-hydroxy-CoA DH from baseline among groups, no 
change post exercise intervention at 12 weeks 
Hiatt56 N=26 (26/0) 
ABI= 0.56 
12 weeks TM, 
RT or C 
Biopsy: LDH, CS, PFK, 
carnitine, TAC, LCAC, 
SCAC 
NS decrease in SCAC, LCAC, TC after 12wk TM training (no 
change vs. control – no exercise), TM training had no effect on CS 
& LDH, but sig ↑ PFK (15 to 18.8) 
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Table 9:  Exercise Training Effects on Endothelial Functioning in Patients with PAD 
STUDY SUBJECTS DESIGN/  PROTOCOL TESTING 
METHODS 
FINDINGS 
Brendle259 N=19 (no 
control) 
6 months – near max 
claudication (15-30 min per 
session) 
Venous Occlusion 
Plethysmography  
30% increase in max blood flow, 15% in RH 
No correlation to improvements in MWD 
Gardner258 N=61 6 months - near max 
claudication (15-30 min per 
session) 
Venous Occlusion 
Plethysmography  
30% increase in max hyperemia (P=0.001)  
77% increase in MWD: Improved Max hyperemia to 
MWD correlation ( r = 0.38, p=0.47) 
Gardner257 N=31 6 months supervised near 
max claudication (15-30 min 
per session 12 months 2 x 
per week 
Venous Occlusion 
Plethysmography  
18% increase in max hyperemia (p˂0.001) 
80% increase in MWD 
Both changes significantly greater than controls 
Gardner256 N=64 (no 
control) – 2 
exercise groups 
6 months (low vs. high 
intensity) 
Venous Occlusion 
Plethysmography  
24% significant increase in MH in exercise group. 
MWD significant increase of 61-63% 
change in MWD correlated to improvements in MH 
(r=0.25, p=0.46)    
Hiatt251 N=19 (10/9) 3 months Venous Occlusion 
Plethysmography  
38% (p˂0.05) change in MH; change not correlated to 
change in MWT 
McDermott57 N = 156 
(51/52/53) 
6 months treadmill vs. 
strength training vs. control 
Brachial Artery Flow 
Mediated Dilation 
Treadmill group mean improvement RH 1.53% (95 CI, 
0.35%-2.70%; P=0.2) and MWT (3.44 min; 95%CI) 
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Table 10:  Potential Mechanisms of Anti-inflammatory and Antioxidant Effects of Exercise Training 
Source Mechanism 
Muscle 
Contraction24-29 
Rhythmic muscular contraction induces the production of the anti-inflammatory myokine IL-6, which has direct inhibitory 
effects on TNF∝ production. Myokine derived IL-6 increases systemic production of other anti-inflammatory cytokines 
including IL-10 and IL-1ra. The anti-inflammatory effects of IL-10 are shown in Figure 4 
Laminar Shear 
Stress263 
An increase in laminar shear stress on the arterial endothelium (present during aerobic exercise) induces the upregulation of 
several atheroprotective genes that lower inflammatory and oxidative stress biomarkers. Genes that are increased are NO and 
MnSOD.  An increase in NO decreases CAM production, while SOD lowers ONOO- formation thereby decreasing oxidative 
cell damage.  
Hormesis33,34,238,316 O2- is a well-known activatior of NFkB, a transcription factor that stimulates proinflammatory cytokine production.  Oxidative 
stress and O2-production also are potent upregulators of enzyzmatic antioxidants, particularly during periods of cellular stress 
(such as during the acute bouts of exercise).  An increase in enzymatic antioxidants will therefore likely decrease oxidative 
induced cellular damage and NFkB activation by RONS. 
Weight Loss & 
Altered Phenotype 
of Adipose Tissue288 
Chronic aerobic exercise training results in the maintenance of the anti-inflammatory phenotype of adipose tissue, which is 
marked by small adipocyte size and the presence of anti-inflammatory immune cells such as TReg cells.  A positive energy 
balance and physical inactivity lead to an accumulation of visceral fat and adipose tissue infiltration by proinflammatory 
macrophages and TH1 cells.   
Mobilization of T-
Regulator Cells289,290 
Chronic aerobic exercise training results in the mobilization of TReg cells (which are potent sources of IL-10 
Downregulation of 
Toll-Like Receptors 
(TLR)279,282 
Exercise training reduces the expression of TLR-4 on monocytes, and thereby induce an anti-inflammatory response marked by 
lower levels of proinflammatory cytokines and reduced adipose tissue infiltration. 
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Source Mechanism 
Ischemia49,51  Ischemia-inducing exercise training increases the production of SOD, HSPs and adenosine, and are potential mediators in the 
IPC response (and therefore a cardioprotective effect of exercise).  HSP-90 can increase the stability of eNOS (thereby 
augmenting the bioavailability of NO), while cells expressing greater concentrations of HSP-72 have greater resistance to 
hypoxic stress and will have a resulting decrease in inflammation and oxidative stress. 
HDL317,318  Exercise can have variable effects on HDL, which has anti-inflammatory and antioxidant properties including;  the inhibition of 
endothelial expression of CAMS and inhibition of LDL oxidation (a important mediator to atherosclerotic foam cell formation). 
Reduction in 
CD14+CD16+ 
Monocytes286,319 
CD14+CD16+ monocytes have 2.5 fold increase in TLR-4 expression on surface compared to the classic CD14+ monocytes.  
Exercise training has been documented to reduce the percentage of the proinflammatory monocyte subtype and have a further 
reduction in TNFα production after stimulation by endotoxin 
Cortisol and 
Catecholamines320,321 
Activation of the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system leads to the release of cortisol and 
catecholamines from the adrenal cortex and medulla respectively.  These hormones can reduce the circulating number of 
CD14+CD16+ monocytes and may additionally inhibit the release of TNFα. 
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Table 11:  Baseline Demographic and Medical Variables 
VARIABLE TM (n=30) 
Mean (SD) or 
n, % 
UBE (n=29) 
Mean (SD) or 
n, % 
Control (n=16) 
Mean (SD) or 
n, % 
Total (N=75) 
Mean (SD) or 
n, % 
P-Value 
Age 66.93 (11.58) 68.41 (8.33) 64.69  (6.04) 67.03  (9.39) 0.449 
Gender:       
   Male 24, 80% 24, 82.80% 11, 68.80% 59, 78.67% 0.55 
   Female 6, 20% 5, 17.20% 5, 31.3% 16, 21.33% 0.59 
Smoking  12, 16% 4, 5.33% 2, 2.67% 18, 24% 0.059 
Total Pack Years 40.68 (27.92) 30.89 (22.48) 31.47 (21.66) 34.67 (24.58) 0.859 
Revascularization 16, 53.3% 11, 37.9% 11, 68.8% 38, 50.67% 0.131 
Diabetes 9, 30% 8, 27.6% 2, 12.5% 19, 25.33% 0.403 
Hypertension 22, 73.3% 25, 86.2% 15, 93.8% 62, 82.67% 0.178 
Dyslipidemia 22, 73.3% 24, 82.8% 14, 87.5% 60, 80% 0.464 
Coronary Heart 
Disease 
11, 36.7% 15, 51.7% 6, 37.5% 32, 42.67% 0.452 
Chronic Heart 
Failure 
2, 6.7% 1, 3.4% 0 3, 4% 0.537 
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Arthritis 2, 6.7% 5, 17.2% 5, 31.3% 12, 16% 0.103 
COPD 3, 10% 2, 6.9% 0 5, 7% 0.431 
Medications      
   Cilostazol 1, 3.4% 1, 3.4% 1, 6.3% 3, 4% 0.874 
   Pentoxyfylline 0 0 0 0  
   Statin 22, 73.3% 24, 82.8% 13, 81.3% 59, 84% 0.650 
   ACE Inhibitor 14, 46.7% 13, 44.8% 10, 62.5% 37, 49.32% 0.489 
   B-Blocker 15, 50% 14, 48.3% 11, 68.8% 40, 53.33% 0.375 
   ASA 24, 80% 21, 72.4% 13, 81.2% 58, 77.33% 0.718 
   Allopurinol 0 3, 10.3% 2, 12.5% 5, 6.67% 0.161 
Supplements      
   Antioxidant 9, 30% 13, 44.8% 5, 31.3%  27, 36% 0.448 
   Omega 3 7, 23.3% 3, 10.3% 0 10, 13.33% 0.071 
 
All continuous data are reported as mean & standard deviation.  Categorical variables are reported as number and percentage. All patients with diabetes 
mellitus were taking oral glycemics or insulin.  (* denotes significance at 0.05 level) 
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Table 12:  Baseline Physiological and Physical Variables 
VARIABLE Treadmill 
(n=30) 
Mean (SD) 
UBE (n=29) 
Mean (SD) 
Control (n=16) 
Mean (SD) 
Total (N=75) 
Mean (SD) 
P-Value 
TNF (pg/ml) 3.41 (1.24) 3.56 (1.35) 3.03 (1.22) 3.39 (1.28) 0.832 
IL-10 (pg/ml) 0.29 (0.25) 0.28  (0.16) 0.22 (0.15) 0.27 (0.20) 0.514 
F2IsoP (pg/ml) 33.35 (30.57) 29.15 (17.83) 41.30 (38.32) 33.43 (28.29) 0.107 
PFWD (m) 109.27 (63.39) 174.57 (99.68) 109.90 (79.71) 134.65 (87.41) 0.175 
MWD (m) 376.78 
(234.08) 
504.30 
(224.31) 
399.24 
(177.41) 
430.88 
(224.52) 
0.870 
ABI 0.71 (0.19) 0.77 (0.17) 0.83 (0.22) 0.75 (0.19) 0.230 
Weight (kg) 87.08 (16.48) 79.83 (21.69) 85.58 (16.96) 83.96 (18.81) 0.773 
BMI 28.99 (4.16) 28.69 (5.01) 29.24 (4.70) 28.93 (4.56) 0.878 
 
All continuous data reported as mean & (standard deviation).  Ankle-Brachial Indices (ABI) are presented for the most symptomatic limb.  BMI 
calculated as mass in kg / height in meters squared.  (* denotes significance at 0.05 level) 
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Table 13a:  Plasma levels of TNF, IL-10, and F2 Isoprostanes (unadjusted values) 
BIOMARKER Baseline 12 wk WGD F-Test P-value 
TNF (pg/ml) 
   Treadmill 
   UBE 
   Control 
 
3.47 (1.24) 
3.57 (1.35) 
3.03 (1.22) 
 
3.56 (1.25) 
3.94 (1.62) 
2.79 (1.31) 
 
0.09 
0.37 
-0.24 
 
3.36 
 
0.040* 
IL-10 (pg/ml) 
   Treadmill 
   UBE 
   Control 
 
-0.67 (0.36) 
-0.64  (0.30) 
-0.75 (0.34) 
 
-0.58 (0.35) 
-0.63 (0.26) 
-0.87 (0.34) 
 
0.09 
0.01 
-0.12 
 
3.40 
 
0.040* 
F2-IsoP (pg/ml) 
   Treadmill 
   UBE 
   Control 
 
1.42 (0.28) 
1.41 (0.22) 
1.49 (0.32) 
 
1.37 (0.33) 
1.35 (0.23) 
1.45 (0.34) 
 
0.05 
0.06 
0.04 
 
0.626 
 
0.538 
TNF is expressed as mean values with (standard deviation) while IL-10 and F2-IsoP are presented as geometric mean values with standard deviation.  P-
values reflect main effects for ANOVA analyses.  (* denotes significance at 0.05 level).  WGD = within group differences 
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Table 13b:  Plasma levels of TNF, IL-10, and F2 Isoprostanes (adjusted for significant covariates and baseline plasma levels of biomarkers) 
BIOMARKER Baseline 12 Wk WGD F-Test P-Value 
TNF (pg/ml) 
   Treadmill 
   UBE 
   Control 
 
3.50 (3.03 - 3.97)a 
3.52 (3.06 - 3.98)a 
2.95 (2.33 - 3.58)a 
 
3.55 (3.28 - 3.81)b 
3.77 (3.50 - 4.03)b 
3.14 (2.78 - 3.50)b 
 
0.05 
0.25 
0.19 
 
4.015 
 
0.022* 
IL-10 (pg/ml) 
   Treadmill 
   UBE 
   Control 
 
0.29 (0.21-0.36)c 
0.28 (0.20-0.35)c 
0.24 (0.12-0.35)c 
 
0.33 (0.28-0.38)d 
0.27 (0.22-0.33)d 
0.25 (0.16-0.33)d 
 
0.04 
-0.01 
0.01 
 
1.84 
 
0.168 
F2-IsoP (pg/ml) 
   Treadmill 
   UBE 
   Control 
 
34.60 (24.55-44.66)e 
27.48 (17.22-37.50)e 
42.04 (28.34-55.73)e 
 
30.63 (23.68-37.58)f 
29.43 (22.39-36.47)f 
34.10 (24.71-43.49)f 
 
 
-3.95 
1.95 
-7.34 
 
0.32 
 
0.731 
Biomarkers are expressed as mean values with 95% CI.  P-values reflect main effects for ANCOVA analyses.  a=adjusted for allopurinol, b=adjusted for 
allopurinol + baseline TNF levels, c=adjusted for diabetes, d=adjusted for diabetes and baseline IL-10 levels, e=adjusted for weight, f=adjusted for 
weight and baseline F2-IsoP levels.  (* denotes significance at 0.05 level).  WGD = within group difference 
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Table 13c:  Plasma levels of TNF, IL-10 and F2 Isoprostanes (adjusted for significant covariates and baseline plasma levels of biomarkers) 
BIOMARKER Baseline 12 wk WGD F-Test P-value 
TNF (pg/ml) 
   Treadmill 
   UBE 
   Control 
 
3.50 (3.03 - 3.97)a 
3.52 (3.06 - 3.98)a 
2.95 (2.33 - 3.58)a 
 
3.55 (3.28 - 3.81)b 
3.77 (3.50 - 4.03)b 
3.14 (2.78 - 3.50)b 
 
0.05 
0.25 
0.19 
 
4.015 
 
0.022* 
IL-10 (pg/ml) 
   Treadmill 
   UBE 
   Control 
 
-0.67 (-0.80 - -0.55)c 
-0.65 (-0.77 - -0.52)c 
-0.74 (-0.94 - -0.54) c 
 
-0.60 (-0.68 - -0.51)d 
-0.65 (-0.74 - -0.56)d 
-0.73 (-0.87 - -0.60)d  
 
0.07 
0 
0.01 
 
1.439 
 
0.246 
F2-IsoP (pg/ml) 
   Treadmill 
   UBE 
   Control 
 
1.43 (1.34 - 1.53)e 
1.39 (1.29 - 1.48)e 
1.50 (1.38 - 1.63)e 
 
1.38 (1.31 - 1.46)f 
1.36 (1.29 - 1.44)f 
1.39 (1.29 - 1.49)f 
 
0.05 
0.03 
0.11 
 
0.150 
 
0.861 
 
TNF is expressed as mean values with 95% CI while IL-10 and F2-IsoP are presented as geometric mean values with 95% CI.  P-values reflect main 
effects for ANCOVA analyses.  a=adjusted for allopurinol, b=adjusted for allopurinol + baseline TNF levels, c=adjusted for diabetes, d=adjusted for 
diabetes and baseline IL-10 levels, e=adjusted for weight, f=adjusted for weight and baseline F2-IsoP levels.  (* denotes significance at 0.05 level).  
WGD = within group differences 
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Table 13d:  Pairwise Comparisons Among Groups for TNF Change 
Pairwise Comparisons 
Dependent Variable:   TNFp   
(I) Group (J) Group Mean 
Difference (I-J) 
Std. Error Sig.b 95% Confidence Interval for 
Differenceb 
Lower Bound Upper Bound 
Treadmill 
UBE -.220 .187 .732 -.680 .239 
Control .408 .225 .223 -.144 .961 
UBE 
Treadmill .220 .187 .732 -.239 .680 
Control .628* .222 .018 .084 1.172 
Control 
Treadmill -.408 .225 .223 -.961 .144 
UBE -.628* .222 .018 -1.172 -.084 
Based on estimated marginal means 
*.#The#mean#difference#is#significant#at#the#.05#level.#
b.#Adjustment#for#multiple#comparisons:#Bonferroni.#
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Table 14:  Effects of Exercise Compliance on Inflammatory Biomarkers 
BIOMARKER Baseline 12 wk F-Test P-value 
TNF (pg/ml) 
   Yes (n=56) 
   No (n=18) 
 
 
3.45 (3.21-3.87)a 
2.90 (2.32-3.48)a 
 
 
3.64 (3.44-3.83)b 
3.26 (2.91-3.60)b 
 
 
3.56 
 
 
0.063 
IL-10 (pg/ml) 
   Yes (n=53) 
   No (n=14) 
 
 
-0.67 (-0.76- -0.58)c 
-0.69 (-0.87- -0.51)c 
 
 
-0.63 (-0.61- -0.57)d 
-0.69 (-0.82- -0.57)d 
 
 
0.839 
 
0.363 
F2-IsoP (pg/ml) 
   Yes (n=57) 
   No (n=14) 
 
 
1.41 (1.34-1.48)e 
1.51 (1.38-1.63)e 
 
 
1.36 (1.31-1.41)f 
1.42 (1.33-1.52)f 
 
 
1.39 
 
0.242 
 
TNF is expressed as mean values with 95% CI while IL-10 and F2-IsoP are presented as geometric mean values with 95% CI.  P-values reflect main 
effects for ANCOVA analyses.  a=adjusted for allopurinol, b=adjusted for allopurinol + baseline TNF levels, c=adjusted for diabetes, d=adjusted for 
diabetes and baseline IL-10 levels, e=adjusted for weight, f=adjusted for weight and baseline F2-IsoP levels.  (* denotes significance at 0.05 level).  
Exercise compliance is defined as performing aerobic exercise 
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Table 15:  Pearson correlation coefficients for baseline inflammatory biomarkers and walking performance variables 
VARIABLE TNF IL-10 F2IsoP 
Baseline PFWD r=0.026 (p=0.828) r=0.166 (p=0.181) r=-0.069 (p=0.554) 
Baseline MWD r=-0.136 (p=0.248) r=-0.073 (p=0.560) r=-0.064 (p=0.585) 
 
IL-10 and F2IsoP correlation values based on geometric means (* denotes significance at 0.05 level 
 
Table 16:  Pearson correlation coefficients among baseline inflammatory and oxidative stress biomarkers 
BIOMARKER TNF IL-10 F2IsoP 
TNF  r=0.232 (p=0.061) r=-0.008 (p=0.944) 
IL-10 r=0.232 (p=0.061)  r=0.101 (p=0.414) 
F2IsoP r=-0.008 (p=0.944) r=0.101 (p=0.414)  
*
IL-10 and F2IsoP correlation values based on geometric means (* denotes significance at 0.05 level) 
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Table 17:  Pearson correlation coefficients among baseline inflammatory and oxidative stress biomarkers on various physical and physiological 
variables 
VARIABLE TNF IL-10 F2IsoP 
ABI r=-0.052 (p=0.658) r=-0.200 (p=0.104) r=-0.085 (p=0.467) 
Weight r=0.159 (p=0.175) r=0.042 (p=0.736) r=-0.311 (p=0.007*) 
BMI r=0.228 (p=0.050*) r=0.124 (p=0.318) r=-0.224 (p=0.053) 
Weight Change r=0.150 (p=0.201) r=-0.124 (p=0.318) r=0.039 (p=0.741) 
 
IL-10 and F2IsoP correlation values based on geometric means (* denotes significance at 0.05 level, **denotes significance at 0.01 level) 
*
*
*
*
*
*
*
*
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Table 18:  Effects of Exercise Dose (Total Minutes Exercised) on Change in Plasma Inflammatory Biomarkers 
VARIABLE QUARTILE 1 
(n=15) 
QUARTILE 2 
(n=15) 
QUARTILE 3 
(n=15) 
QUARTILE 4 
(n=15) 
Minutes exercised  1072.10 (227.61) 1421.91 (164.44) 1557.27 (218.76) 1580.69 (38.82) 
TNF change 0.34 (0.79) 0.30 (0.53) -0.27 (0.71) 0.44 (0.64) 
IL-10 Change 0.02 (0.19) -0.09 (0.17) 0.06 (0.30) 0.07 (0.23) 
F2IsoP Change -0.06 (0.22) -0.09 (0.20) -0.02 (0.28) -0.36 (0.11) 
Weight Change -0.51 (1.55) 0.22 (1.52) -0.79 (2.73) -0.41 (1.97) 
 
All values expressed as means and standard deviations.  IL-10 and F2IsoP values based on geometric means (* denotes significance at 0.05 level, 
**denotes significance at 0.01 level) 
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Table 19:  Pearson correlation coefficients among exercise dose and change in plasma inflammatory and oxidative stress biomarker change 
VARIABLE QUARTILE 1 
(n=15) 
QUARTILE 2 
(n=15) 
QUARTILE 3 
(n=15) 
QUARTILE 4 
(n=15) 
TNF change r=0.03 (p=0.912) r=-0.12 (p=0.687) r=0.36 (p=0.190) r=-0.21 (p=0.457) 
IL-10 Change r=0.04 (p=0.898) r=0.61 (p=0.028*) r=-0.06 (p=0.856) r=-0.32 (p=0.286) 
F2IsoP Change r=-0.22 (p=0.460) r=-0.45 (p=0.105) r=-0.10 (p=0.741) r=-0.26 (p=0.926) 
Weight Change r=0.14 (p=0.618) r=-0.24 (p=0.413) r=0.05 (p=0.853) r=-0.32 (p=0.244) 
IL-10 and F2IsoP correlation values based on geometric means (* denotes significance at 0.05 level 
Table 20:  Effects of Exercise Training on Body Weight and BMI 
Variable Treadmill (n=30) UBE (n=30) Control (n=15) F-Test p-value 
Weight  
- BL 
12wk 
 
87.08 (16.48) 
86.40 & 16.54 
 
79.83 (21.69) 
82.80 & 15.59 
 
85.57 (16.96) 
83.90 & 16.75 
 
 
0.391 
 
 
0.678 
BMI 
- BL 
12wk 
 
28.99 (4.17) 
28.42 (3.75) 
 
28.69 (5.01) 
29.98 (5.05) 
 
29.24 (4.69) 
28.67 (4.67) 
 
 
0.22 
 
 
0.98 
 
Weight is expressed as mean (kg) & (standard deviation), BMI expressed as mean & standard deviation. (* denotes significance at 0.05 level)  
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Figure 2:  Theoretical Framework for Anti-Inflammatory Effect of Exercise in PAD 
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#
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Figure 3:  Effects of Inflammation 
and Oxidative Stress on 
Endothelial Function, and the 
Therapeutic, Anti-inflammatory 
Effects of Aerobic Exercise 
Training. 
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FIGURE*5:**AntiNInflammatory*Mechanisms*of*Interleuken*10*(ILN10)*
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                  Figure 8a  
 
                                                              Mean TNF change is expressed in pg/ml.  
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Figure 9  
                                            TNF expressed in pg/ml:  BMI is expressed in kg/m2  
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